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ABSTRACT
Vinyl Chloride Monomer (VCM, CAS # 75-01-4) is one of the few chemicals identified as a
human carcinogen (lARC, 1979). In this report, the toxicity and mutagenicity of VCM and
its two metabolic products, 2-chloroethylene oxide (CEO) and 2-chloroacetaldehyde (CAA)
were studied in a human B-lymphoblastoid line containing cloned cytochrome P450IIE1.
Cytochrome P450IIE1 is capable of metabolizing VCM to CEO which non-enzymatically
rearranges to CAA. Toxicity was determined by plating cells immediately after exposure and
comparing their clone-forming ability to that of untreated cells. Mutagenicity at the hprt
locus was determined by plating cells in the presence of the selective agent 6-thioguanine.
Delivered doses of 25 mM to 400/iM VCM x 24 hours produced no measureable toxicity but
resulted in induced mutation frequencies that ranged from 0.5xl0'"to 5.6x10"". Although
increases in mutation frequency were consistently seen, a clear dose-response was not
apparent. Dose dependent increases in toxicity and mutagenicity were observed with both
CEO and CAA. Treatments of 25 mM CEO x 24 hours resulted in survival of 0.82 and
induced mutation frequency of 8x10" , while similar treatments with CAA produced a
survival of 0.06 and induced mutation frequency of 9x10"". Comparison of mutation
frequency/ survival ratios for the three compounds at the same induced mutation frequency
suggest the majority of mutations induced by VCM must be produced by CEO.
Denaturing gradient gel electrophoresis (DGGE) was used to identify unique VCM,
CEO, and CAA mutations in exon 3 of the hprt gene. DGGE banding patterns from CAA
and CEO isolated mutants were compared to the banding patterns from VCM. 118 VCM
mutants analyzed in the low temperature melting domain of exon 3, 8.5% (10 isolates)
produced identical DGGE banding patterns; sequencing of the isolated mutant bands revealed
a G-T transversion at base pair 292. In the high temperature melting domain, 3.4% (4 of 118
isolates) exhibited identical DGGE bands; sequencing revealed a G-»A transition at base pair
197. These sequence changes represent potential VCM mutational "hotspots". The low-
temperature "hotspot" banding pattern was evident in less than 2% (1 isolate) of the
spontaneous mutants in the VCM experiment. However, it was present in 5.6% (11 isolates)
of the CEO mutants analyzed.
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FOREWORD
The identification of biomarkers that can serve as indicators of human exposure to
specific chemicals is an important goal of the study of carcinogenesis. The use of biomarkers
takes into account a variety of factors affecting a compound's toxicity, including differences
in route of uptake, the metabolism to activate or detoxify the compound, the ability to excrete
the compound or its metabolites and the ability to repair damage (Wogan, et al., 1987).
Biomarkers include a broad range of analytical targets that can be grouped in two general
categories: 1) measurements of concentrations of chemicals or their derivatives in body fluids
or excreta, and 2) measurement of biological reaction products such as DNA adducts,
mutation, chromosomal abberations or sister chromatid exchanges produced in the tissues of
exposed individuals (Wogan, et al., 1987). Two important elements of a biomarker are 1) its
relevance to the exposure of concern (correlation of the measured biomarker to an adverse
human health effect); and 2) the sensitivity of the biomarker, (whether it can detect
differences between exposed and non-exposed individuals).
DNA adduct formation is an endpoint relevant to exposure to genotoxic agents.
Furthermore, it can be measured with sufficient sensitivity to differentiate between exposed
and non-exposed individuals and can function over a wide range of doses (Swenberg et al,
1990). The molecular dose of a compound is the actual amount of chemical that reacts with
macromolecular targets, such as DNA. This dose is very small in comparison to the
environmental concentration of the chemical (Swenberg et al., 1990). The determination of
DNA adducts can clarify the relationship between the extemal exposure and the molecular
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dose, at exposure concentrations which are much less than those used in bioassays (Swenberg
etal., 1990).
DNA adducts do not always lead to mutations. Replication of the DNA is required to
convert the adducts formed (promutagenic lesions) to actual mutations (Swenberg et al.,
1990). DNA repair systems can repair some of the adducts before replication of DNA thus
avoiding mutation. Also, many adducts are intrinsically nonmutagenic while others are very
promutagenic. Some sites on DNA called, "hot spots", are more susceptible than other
locations to the effects of chemical agents (Benzer, 1961 and Briscoe et al., 1984). Many
mutagens exhibit characteristic patterns of mutation in the DNA that can be distinguished by
comparison to pattems of mutation induced by spontaneous processes or by other mutagens
(Fuchs, 1981; Skopek, 1982; Duane, 1986; Schaaper, 1986; Drobetsky, 1987; Richardson,
1987; Giroux, 1988; Vrieling, 1988; Liber, 1989).   The pattems of these mutations are
termed mutational spectra. Within these spectra, the active locations or "hot spots" can
readily be discriminated by the location, type and frequency of the mutation in relation to
other mutational events. Because of this mutational specificity, the base pair changes
produced by the mutagen can imply additional information about the DNA adducts and the
molecular events that produce the mutations (Fuchs, 1981; Skopek, 1982; Duane, 1986;
Schaaper, 1986; Drobetsky, 1987; Richardson, 1987; Giroux, 1988; Vrieling, 1988; Liber,
1989). The study of DNA adducts and mutational spectra can help to determine causal
relationships and may improve extrapolation of risk for cancer from experimental animals to
humans.   Measurement of DNA adducts and mutational spectra may also be used in
biomonitoring programs to increase the power of these studies to detect early health hazards.
IX
VCM is a proven human carcinogen and exposures are still a concern. The goal of the
present project was to identify characteristic sequence changes induced by VCM and its
metabolites, CEO and CAA. These specific mutation pattems could ultimately serve as
biomarkers relevant to VCM exposure. Furthermore, these changes can be used to aid in
determining which DNA adduct(s) is (are) involved in VCM mutagenesis; these adducts
would serve as additional relevant indicators of health threats due to VCM exposure.
SPECIFIC AIMS
The primary goal of the planned work was to study the frequency and nature of
mutations induced by VCM and its metabolites, CEO and CAA, in a human cell Mne. This
information would then be used to conclude which metabolite is mainly responsible for the
mutagenic activity of VCM. Specifically, the following two aims were proposed:
1. To determine the toxicity and mutation frequency at the hprt gene induced by VCM,
CEO, and CAA in a human lymphoblastoid cell line expressing cytochrome P450IIE1.
2. To characterize the mutational spectra of VCM, CEO, and CAA using denaturing
gradient gel electrophoresis technology and DNA sequencing.
CHAPTER I
TOXICOLOGY OF VCM
Vinyl Chloride is a synthetic chlorinated monomer manufactured from petrochemical
feedstock and chlorine. The compound is a colorless, explosive gas with a boiling point of
-14" C at atmospheric pressure and is slightly water soluble (EPA, 1975). About 96% of the
VCM manufactured worldwide is used in the production of vinyl chloride homopolymer and
copolymer resins. One of the major commercial products made with VCM is polyvinyl
chloride (PVC) which is then used in the manufacture of a myraid of products (Sax, 1988).
The estimate for vinyl chloride production in the U.S. for 1993 is approximately 11.0 billion
pounds (ATSDR, 1992). The Occupational Safety and Health Administration (OSHA) has
set a regulatory standard for VCM exposure in the workplace of 1 part per million (ppm)
weighted over an 8-hour time period. Other OSHA regulations prohibit operations which
result in VCM coming in contact with the skin. The National Institute of Occupational
Safety and Health (NIOSH) has recommended the lowest limit of detectability as the limit for
a ten-hour averaged exposure (Sax, 1988). A NIOSH survey conducted from 1981-1983
estimated that 81,000 U.S. workers are potentially exposed to VCM in the workplace
(NOES, 1990).   The major route of VCM exposure in an industrial setting is through
inhalation; however, skin absorption is possible in the cleaning of polymerization ovens. In
the 1970's the acute effects seen in VCM polymerization workers were believed to be the
only hazardous properties of vinyl chloride. Monitoring of vinyl chloride at this time was
directed primarily toward maintaining levels below the lower explosive limit (LEL) of 4%
(Sax, 1988). Because of the low level of concern and the high levels permitted, VCM
workers (especially those who cleaned the polymerization ovens), could have been exposed
to levels in the thousands of parts per million (Purchase et al., 1987). This speculation agrees
with reports that VCM oven workers would be removed from the work area in an
unconscious or semi-conscious state due to the high levels of VCM exposure. Acute
exposure to VCM in levels over 10,000 ppm can cause central nervous system depression,
dizziness, lightheadedness, nausea, dulling of the senses and headache (Lester et al., 1963).
Additionally, two fatalities had been reported in 1960 due to extremely high acute exposures
(Danziger, 1960). Chronic adverse health effects are also seen from VCM exposure. These
effects include: degenerative bone changes, circulatory disturbances, thrombocytopenia,
spleenomegaly, hepatomegaly and hepatic fibrosis (La Dou, 1990). More central to the focus
of this research is the confirmation that angiosarcoma of the liver, a rare form of liver cancer,
is caused almost exclusively by VCM exposure and is an often studied endpoint for chronic
exposures (Purchase et al., 1987). Since 1974 there have been 118 cases worldwide of
angiosarcoma of the liver reported to a central registry. Most of these individuals were
workers involved in the cleaning of ovens used for VCM polymerization. This registry,
along with numerous epidemiological studies estimate an additional 200-350 deaths over the
next 30 years associated with past VCM exposure (Forman et al., 1985). The level of
exposure to VCM capable of causing angiosarcoma has not been definitively shown to cause
any other carcinogenic effects in man, as indicated by epidemiological studies with endpoints
other than angiosarcoma (Purchase et al., 1987). This is another reason why most cohort
studies of VCM workers use angiosarcoma of the liver as a definitive endpoint. Many
epidemiological studies have centered on VCM workers, and a summary of these studies can
be found in separate reviews by I.F.H. Purchase et al. (1987), and Sax (1988). These studies
looked at a variety of cancer sites including liver, lung and brain. The excess liver cancers
found in most of these studies was due to an excess of angiosarcoma. One retrospective
cohort study of 1151 workers at four vinyl chloride production facilities with over 12,000
person years at risk demonstrated that of the fourteen cases of biliary and liver cancer
observed, eleven were cases of angiosarcoma (Sax, 1988). While the preponderance of
epidemioligical data strongly indicate that exposure to vinyl chloride increases a persons risk
to a variety of cancers, angiosarcoma of the liver is the only cancer type that can be
attributed unambiguously to VCM exposure.
Environmental sources of VCM contamination include product manufacturing and
hazardous waste sites (EPA, 1985, Stephens et al., 1986). VCM was identified in at least
10% of the hazardous waste sites listed on the Environmentnal Protection Agency's National
Priorities' List (NPL). Vinyl chloride eminating from VCM and PVC processing faciUties
accounts for the majority of VCM entering the environment. VCM has a half-life in the
environment of only 1-2 days as sunlight will cause the monomer to polymerize. People who
live near production facilities are the only segment of the non-occupationally exposed public
to receive any measureable exposure. Their estimated daily intake of VCM is from 0-2,100
Mg/person/day (ATSDR, 1992). Other potential routes of non-occuaptional VCM exposure is
from ingestion of food and water contaminated with VCM through leaching of packaging
material and pipes. A study on bottled water estimated the average daily intake of VCM at
120ng VCM/person/day if bottled water were the only source of drinking water. Many pipes
that supply homes drinking water are made from PVC and the potential exists that the
migration of uncured monomer from the pipes is contributing to the total amount of VCM
ingested (Benfanati et al., 1991). VCM is also produced via the natural anerobic microbial
degradation pathways of two of the most common pollutants at hazardous waste sites,
trichloroethylene (PCE) and perchloroethylene (Vogel et al., 1985).
Vinyl chloride is metabolized through an NADPH-dependent cytochrome P450IIE1
mixed function oxidase system to the reactive species 2-chloroethylene oxide (CEO), which
non-enzymatically rearranges to form 2-chloroacetyldehyde (CAA). Both CEO and CAA are
highly reactive and are capable of modifying DNA. Consequently, the carcinogenic effects
of VCM have been attributed to these electrophillic metabolites rather than the parent
compound (Miller, 1976). The general reaction and rearrangement for this process is given
in Fig. 1-1:
DNA
CI
CyP450
HC=CCIor-H,C^^CHg-z-CHJCHO^ LI NADPH   ^    \     / ^3 ^ '" \/     I CI
(From Purchase et al., 1987 and Zajedela et al., 1980)
VCM is similar to many other industrial chemicals, in that its adverse effects are
attributable to one or more of the metabolites. The concentration of metabolite produced
from a parent compound does not continue to increase proportionately with increasing levels
of exposure. Extremely high doses of a chemical can overwhelm the metabolic system
responsible for activating or detoxifying the compound. Gehring et al.,(1978) discovered
that the toxicity of vinyl chloride exposed male Sprague-Dawly rats was a saturable process
following Michaelis-Menten kinetics. Using ^^C labeled VCM, they measured total
radioactivity in animals sacrificed zifter equal exposure time to various concentrations of
VCM. They discovered that the amount of VCM metabolized reached a plateau between 9
and 25 parts per million (ppm). They also concluded from this study that VCM-induced
angiosarcoma is a function of the metabolic activation rather than the exposure concentration
(Gehring et al., 1978).
A large number of in vivo animal studies as well as in vitro studies have been carried
out to examine the mechanism of action of VCM. An extensive listing which summarizes
these studies is provided in Sax (1988).
Work by C. MalaveUle et al. (1975), using histidine reversion in S. typhimurium as an
endpoint, demonstrated the need for metabolism in VCM mutagenesis. They exposed
bacteria to gaseous VCM, both with and without S-9 liver fractions from humans, rats and
mice. They demonstrated a mutagenic effect from CAA and an even greater effect from CEO
in bacterial strains which revert by base pair substitution. No mutagenic activity was
demonstrated in strains reverted by a frameshift (Maleville, et al., 1975). In the same study,
using the 4-(p-nitrobenzyl)pyridine assay with CEO or CAA, they determined that CEO
possess a greater alkylating activity than CAA. In a review of in vitro studies involving
VCM exposure to microorganisms and VCM exposures to Chinese hamster ovary cells,
Bartsch et al.,(1976) concluded that both CAA and CEO are mutagenic in these test systems,
but that CEO was far more effective; in bacterial studies the difference was as great as 1000
fold (Bartsch et al., 1976). They concluded that CEO was the metabolite most responsible
for the mutagenic effects of VCM.
Guengerich et al., (1979) using reconstituted and microsomal cytochrome P450 from
rats concluded that CEO was the alkylating agent involved in conversion of adenosine to
l,N"-ethenoadenosine. 1,N°- Ethenoadenosine was not produced by CEO when epoxide
hydrolase was present, but formation did occur in the presence of alcohol dehydrogenase.
They concluded through this and earlier studies that CEO is sufficiently reactive to alkylate
DNA efficiently, but is not so reactive as to bind solely to P450 proteins (Guengerich, et al.,
1979).
L.M. Gwinner et al., ( 1983) compared alkylation produced by VCM and 2,2'-
dichlorodiethylether (BCME) in hepatocytes of male Wistar rats. The latter compound is
metabolized completely to CAA (partly through an intermediate). They concluded that CAA
was responsible for protein alkylation while the VCM (and therefore CEO) was mainly
responsible for binding to DNA. This study was unique in its use of BCME which is
oxidized to CAA and 2-chloroethanol (CE), which in tum is completely metabolized to CAA.
Unlike VCM, 2,2'-dichlorodiethyl ether does not pass through a reactive epoxide;
consequently, effects from the epoxide and the aldehyde could be differentiated in vivo,
something heretofore only possible in vitro (Gwinner, et al., 1983).
Zajdela et al. administered CEO subcutaneously to eight-to ten-week- old male and
female XVUnc/Z mice. The same was done with BCME, a compound that is a direct acting
human and animal carcinogen, similar in structure to CEO. Tumor formation from CEO was
comparable to BCME. CAA was also included in this study, but was used in an
initiation/promotion skin painting experiment (CAA could not be tested subcutaneously
because of its necrotizing effects). VCM and CEO were also used in the painting study. 12-
8O-n-tetradecanoylphorbol-13-acetate was used as a promoter with all three chemicals. Both
CEO and BCME produced skin tumors, while CAA did not. These results led them to
conclude that CEO was the reactive metabolite of VCM and therefore, responsible for its
carcinogenic activity. (Zajdela et al., 1980).
In conclusion, CAA and CEO were demonstrated to react with DNA in vitro causing
mutations, however CEO was more strongly mutagenic. Additionally, CEO was
carcinogenic in vivo while CAA was not. This brief summary of the growing body of
evidence in numerous in vivo and in vitro test systems strengthens the following conclusions
about VCM: 1) VCM requires metabolic activation to exert its mutagenic and carcinogenic
effects, 2) CEO and CAA, two reactive products of metabolism manifest their effects in
different ways, 3) CAA, although the more cytotoxic compound, shows less mutagenic
potential in vitro and less carcinogenic potential in vivo compared to CEO.
DNA Adduct Formation and Relevance
DNA is a highly nucleophilic molecule and contains thirteen potentially reactive sites
(Singer, 1985). Chemicals which are strongly electrophilic are capable of reacting with these
sites and producing modified DNA bases. Upon DNA replication these modified bases can
result in base mispairings at the adduct site.   The electrophilic attack of chemicals can result
in a wide variety of DNA adducts (Swenberg, 1990). Both CAA and CEO can react with
nucleophilic cellular macromolecules, including DNA and can form stable DNA adducts.
Several factors control the probability of an adduct undergoing a mispairing event in
DNA. First, modified bases differ in their ability to base pair in DNA, possibly due to
differences in hydrogen bonding between the two Watson-Crick paired bases. The length of
time that an adduct remains on the DNA is also an important factor in the ultimate biological
outcome of DNA modification. This is dependent on both the chemical stability of the
adduct and the function and availability of various DNA repair enzymes (Singer, 1985).
The production of DNA adducts shows specificity for certain sites on the DNA
(Richardson 1989, Warpehoske 1988). The propensity of sites to react is affected by the base
adducted and usually the neighboring base or bases (5' or 3'). The differences in reactivity
no doubt contribute to "hot spots" and cold spots of base substitutions (Cooper, 1990). The
frequency of mutations occurring at different modified bases may be influenced by several
factors including differences in repair efficiencies and differences in the rate of base
misinsertion, both of which are expected to be influenced by local DNA sequence context.
Briscoe and Cotter conducted a study in 1984 to determine whether there was any effect of
cytosines or guanines as nearest neighbors upon the alkylation of a guanine residue in DNA.
N-methyl-N-nitrosourea (MNU) was reacted with a synthetic polynucleotide. They
concluded that the alkylation pattern of guanine was dependent on the neighboring bases and
this finding would be relevant in defining hot spots of mutational activity within a genome
(Briscoe et al., 1984). Richardson et al., (1989) investigated the formation of O"-
methyldeoxyguanosine (0"MedGuo) from N-methyl-N-nitrosourea at four specific sites in a
synthetic oligonucleotide resembling a mutational hotspot in the Esherichia coli xanthine-
guanine phosphoribosyltransferase gene. The sites studied on the oligonucleotide were
tritiated and the formation of 0"MedGuo quantitated. It was determined that the site where
0"MedGuo most frquently formed corresponded to the site frequently mutated in E. coli by
the same compound. The O MedGuo formation was not random along the oligonucleotide
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and the distribution was only evident in the dsDNA oligonucleotide tested, not the ssDNA.
These results suggest a sequence dependent mutation site that is also dependent on the
secondary DNA structure (Richardson et al., 1989).
In vivo and in vitro studies by Laib et al., (1981) concluded that the DNA adduct N -
(2-oxoethyl) guanine (7-OEG) was the major product of alkylation from the reactive VCM
metabolites. This was true both for rats exposed to [1,2-^^C] vinyl chloride and in vitro
studies with rat liver microsomes, an NADPH-regenerating system, DNA and [    C] vinyl
chloride (Laib, et al., 1981). It was proposed that this adduct in the cyclic hemiacetal form
could be read by the polymerase as adenine and therefore cause mispairing. However
numerous studies have shown that modification at the N7 position of guanine does not
prompt mispairing. Alkylation at the N7 position does promote depurination which can also
occur spontaneously or through the action of glycosylases. Apurinic sites have been shown
to be promutagenic but their production and conversion to mutations is expected to be
inefficient relative to other adducts formed by VCM (see below). Therefore, even though 7-
OEG accounts for up to 98% of the modified bases in DNA, it was predicted that it would
contribute little to induction of mutagenicity by vinyl chloride or its metabolites (Barbin et
al., 1985; Laib et al., 1981; Swenberg et al., 1990). Furthermore, it has a half-life of
approximately 62 hours in DNA and therefore is not extremely persistent (Fedtke et al., 1990,
Swenberg et al., 1990).
Different methods of adduct detection and quantification revealed an additional three
adducts formed by the interaction of DNA with the metabolites of VCM. These are: 1,N"-
etheno-2-deoxyadenosine (cdAdo), 3,N^-etheno-2-deoxycytidine (edCyd); and the most
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recently identified VCM adduct N-^,3-ethenoguanine (N^,3eG) (Singer, 1983). These
adducts and the point mutations which have been inferred to result upon DNA replication are
pictured in figure 1.2.
The biological importance of these adducts in mutagenesis and carcinogenesis remains
to be determined. As stated above, 7-OEG is found in vivo and in vitro in the greatest
concentrations relative to other VCM adducts, but no studies have demonstrated the
mutagenic properties of this adduct. Laib et al., (1985) identified the presence of N'^,3 eG in
VCM-exposed fourteen-day-old rats.   Singer et al., (1987) went on to determine that this
adduct can act like a guanine or adenine (in reference to recognition by DNA polymerase)
causing GC-»AT transitions approximately twenty percent of the time. Their study involved
the synthesis of N'',3 eG, and its copolymerization with cytosine diphosphate (CDP) into an
oligonucleotide. They then measured the rate of incorporation of incorrect nucleosides using
the oligonucleotide as a template. Based on these results, they proposed that N'^.S eG is an
important promutagenic adduct of vinyl chloride (Singer et al., 1987). Fedtke, et al., (1990)
'yStudied the formation and persistence of both 7-OEG and N'^,3 eG in target and non-target
tissues of preweanling Sprague-Dawley rats exposed 5 days to gaseous VCM. The ratio of
/y
N ,3 eG:7-OEG was 1:100 in animals analyzed immediately after exposure.   This value
changed dramatically in animals analyzed at two weeks (1:14.1) indicating the greater
persistence of N'^,3 eG. From their study they calculated a half-life of 62 hours for 7-OEG
and greater than 30 days for N ,3 eG (Fedtke, et al., 1990). These results suggest the
N'',3eG is likely to accumulate to high levels in vivo (Swenberg et al., 1990).
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Eberle et al., (1989) raised monoclonal antibodies to edAdo and edCyd to permit their
quantification in vivo. Young Sprague-Dawley rats were exposed by inhalation to 2000 ppm
of VCM for ten days and the levels of edAdo and edCyd were quantified in the lung and
liver tissues through the use of the Mabs. Both adducts were found in lung and liver tissues,
with greater concentrations of both in the lung. Additionally, the levels of edCyd were 2.5
times and 3.2 times higher in the lung and liver, (respectively), than the levels of edAdo.
These results demonstrated that both of these adducts were formed efficiently in vivo during
VCM exposure (Eberle, et al., 1989).
To determine whether CEO or CAA is primarily responsible for the formation of these
minor, yet persistent and promutagenic adducts Guengerich et al., (1992) reacted these
compounds directly with calf thymus DNA (Guengerich et al. 1992). They found that the
etheno adenine and guanine adducts were formed much more effectively by CEO than CAA
(by at least an order of magnitude). The key to their study was the conditions of metabolism
of vinyl chloride. l,N"-ethenoadenosine (edAdo) formation was almost completely blocked
(from either DNA or adenosine) when purified epoxide hydrolase was included in the
reaction, but when the CAA destroying enzyme (alcohol dehydrogenase) was added, there
was little effect on edAdo formation. The in vitro study indicated formation of adducts from
CEO exposure at the following relative levels : 7-OEG » edAdo > N^,3 eG. The lack of
formation of 7-OEG by CAA in this in vitro study was consistent with the reported lack of
formation in vivo. The very low levels of edAdo and N^,3 eG formation from CAA led the
authors to conclude the CEO is the major metabolite responsible for DNA alkylation
(Guengerich, 1992). These results have led the authors to conclude that both DNA adducts
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N ,3 eG and edAdo are formed in DNA primarily through the reactive epoxide versus the
aldehyde.
As mentioned previously, 7-OEG is not expected to demonstrate any miscoding
properties in DNA. This is not the case for the other three eidducts, all of which have
demonstrated miscoding properties.  edAdo was found to be a miscoding lesion during RNA
transcription, resulting in AT-»GC transitions and AT->CG and AT-»TA transversions
(Spengler and Singer, 1981, de los Santos et al.,1991).  edCyd was found to cause errors
during both DNA replication and RNA transcription, resulting in CG-»AT transversions,
CG-»TA transitions, and, at a much lower frequency, CG->GC transversions (Spengler and
Singer, 1981; Singer and Spengler, 1986). As mentioned previously, the adduct, N'',3eG
causes GC->AT transitions during replication.
Because of the efficiency of formation of these etheno DNA adducts of VCM, their
promutagenic properties and persistence in DNA, exposures to even very low concentrations
of VCM could pose a significant health risk (Swenberg, 1991). The work with VCM and its
metabolites in this research will provide additional information on the role of CEO and CAA
in VCM mutagenesis in human cells and contribute to the knowledge of the molecular nature
of VCM-induced mutations.
Mutagenicity
A mutation in DNA can be defined as a stably inherited change in the ordering of
nucleotide bases in the genome. An organism with a genomic change is called a mutant (for
that change) and the same organism without the change is referred to as wild type. The
frequecy of occurance of mutants in a population is referred to as the mutation frequency
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(MF) and represents the fraction of mutants in the population. Mutations can be classified in
several categories.  A point mutation affects only a single base in the DNA. The most
common form of point mutations are substitutions, of which there are two types. Transitions
substitute one pyrimidine base for another or one purine base for another purine (AT->GC,
CG-»TA) and transversions exchange a purine for a pyrimidine or a pyrimidine for a purine
(AT-+CG,TA; GC->TA,CG). Point mutations can lead to three outcomes in the transcription
of the changed sequence. There may be no change at all in the amino acid sequence from the
wild type to the mutant sequence; this is due to the degenerate nature of the code. The
change can result in a "missense" mutation, in which a different amino acid is inserted. This
can affect a unique enzymatic function of the cell resulting in reduced or negUgible enzyme
activity, or possibly a new function. If the change in sequence results in the production of a
stop codon, then premature termination of protein synthesis will occur. This type of change
is called a "nonsense" mutation. Rearrangements usually effect large portions of the gene
and are manifested through the loss (deletions) or gains (insertions) of nucleotides into the
DNA. Mutations of this kind can result in shifts of the reading frame of the DNA sequence
due to the fact that information is stored in codons consisting of three nucleotides (Lewin,
1990).
Mutations can also be classified as to their general causative source.   "Naturally-
arising" mutations are usually called spontaneous mutations and the level at which they occur
for an organism (or cell line) is termed the background mutant frequency (MF). This level of
mutation can be determined from the zero treatment controls used for the mutation studies.
The cell line used in the current study has an average background MF at the hprt locus (see
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chapter II) of 3.0x10"" (or three mutants out of one million wild type cells with HPRT
activity) (Gentest, 1990). These spontaneous events can arise due to a variety of causes
including the processes of DNA replication and DNA repair. Giroux et al., (1988) in a study
to determine the DNA sequence of 196 spontaneous mutants in the SUP4-0 gene of S.
cerevisiea identified all possible types of base pair substitutions, deletions, and complex
alterations involving multiple changes, as well as insertions and transpositions. Their work
led them to support the hypothesis that many spontaneous mutations are actually the result of
DNA sequence-directed events (Giroux et al., 1988).   Similar results were obtained by
Schaaper et al., (1986) in their analysis of the spectmm of spontaneous mutation in the
Escherichia coli lac I gene. They analyzed 174 spontaneous mutations and determined that
the spectrum consisted of base pair substitutions, frameshifts, deletions, dupUcations, and
transpositions. These results led them to conclude that the spontaneous mutations occurring
in the organism studied were the result of a variety of endogenous mutational mechanisms
(Schaaper, et al.,1986). Mutations induced by chemical or physical damage can be
ascertained in a test system when the level of mutations induced is significantly greater than
the level of spontaneous mutations. The level of MF increase over background determines
the strength of mutagenic compounds and allows for their comparison. Many mutagenic
compounds exert their effect by covalently binding to (adducting) a particular base or
intercalating (Lewin, 1990). If this bound chemical/DNA complex is stable it can be
processed through the repair, replication, and recombination systems of the cell, and may be
converted to a mutation (Fuchs, et al., 1981).
•
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Vinyl chloride was shown to be mutagenic in many test systems including bacteria
(Escherichia coli K12, Salmonella typhimuriwn TA1530, TA1535, 646) yeast
(Schizosaccharomyces pombe) and Drosophila melanogaster. All of the in vitro studies
indicated the necessity for some metabolic activation system for the compound to show
definitive mutagenicity (Sax, 1988).
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Fig 1.2. Identified DNA adducts from in vitro and in vivo exposures to VCM and its
metabolites along with inferred base pair changes. Compiled from: Barbin et al., 1985; Laib et
al., 1981; Swenberg et al., 1990; Spengler and Singer, 1981; de los Santos et al., 1991; Singer
and Spengler, 1986.
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The hypoxanthine phosphoribosyl transferase (hprt) gene was the genetic target used in
all the mutation assays reported here.   HPRT (protein) is a purine salvage enzyme that
catalyzes the condensation of free hypoxanthine or guanine with 5-phosphoribosyl-l-
pyrophosphate (pp-ribose-p). Although non-essential for cells growing in culture, the lack of
HPRT can have serious effects in man. Complete lack of HPRT activity results in the genetic
disease known as Lesch-Nyhan syndrome (Holden et al., 1978). Less severe deficiencies can
result in gouty arthritis (Kelly et al., 1967). HPRT enzyme activity has an influence directly
or indirectly on cellular processes related to purine synthesis. This is known primarily
through examination of people with gout who have been shown to exhibit elevated rates of
purine synthesis (Caskey, 1979).
Hprt is located on the long arm of the X chromosome (Holden et al., 1978) and
consists of nine exons and eight introns which total 57,000 base pairs in length. The
molecular weight of HPRT is 24,300, and it exists in vivo as a tetramer (Holden, 1978).
Since hprt is located on the X-chromosome, males possess only one copy and females
possess only one active copy due to X-chromosome inactivation. Consequently, hprt is
effectively hemizygous in both males and females and only a single mutational event is
required to render a cell phenotypically hprt". HPRT substrates include: hypoxanthine,
guanine, 6-mercaptopurine, and 6-thioguanine (6TG) (Krenitsky et al., 1969).
The key advantage for the use of hprt in gene mutation studies is the existence of
stringent selective conditions for both hprt"*" and hprt' phenotypes. Hprt"*" cells can be
selected in media containing hypoxanthine, aminopterin and thymidine (HAT). Aminopterin
inhibits purine (and thymidine) de novo synthesis and its presence forces a cell to rely on its
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salvage pathways (hprt, tk) for survival. Hprt"'' ceUs can phosphoribosylate and utilize
hypoxanthine in HAT media and grow, while hprt" cells cannot (Thomas, 1979; see figure
2.1.) The process of treating a cell culture in HAT media prior to a mutation study reduces
the level of background mutants (those caused by means other than the test substances) and
increases the sensitivity of the assay.
When grown in the presence of 6TG a cell with active HPRT will metabolize 6TG to
the ribonucleoside monophospate 6-thioGMP (6TGMP). 6TGMP is further metabolized,
incorporated into nucleic acid and kills the cell. Consequently, hprt"^ cells are killed in the
presence of 6TG   (Nelson, 1975).   However, cells without HPRT activity (hprt*) cannot
phosphoribosylate 6TG zmd can survive and grow in its presence. The ability to select hprt'
mutants provides a straight-forward means to detect mutation induction resulting from a
chemical exposure.
Cells mutated at the hprt locus no longer produce functional hprt mRNA; however, for
a period of time they still possess HPRT enzymatic activity due to the presence of preexisting
hprt mRNA and HPRT proteins Prior to 6TG-mediated selection, the cells must pass through
several cell cycles (without selection) to ensure that newly formed hprt' cells lose their
residual HPRT activity. This length of time is known as the phenotypic expression period
and for most cells is greater than five days (Crespi, 1984).
The hprt locus has been widely studied and the types of mutations fi"om different
chemicals reported. A review of the hprt locus by Caskey in 1979 indicated studies at that
time had demonstrated missense mutants (point mutations), frameshifts, deletions, and
suspected premature chain termination mutations (nonsense mutations) (Caskey et al., 1979).
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Subsequent studies verified and added to the location, type and frequency of mutations at
hprt in different systems. Cariello et al., (1988) identified a point mutation in hprt in a
patient with gout, utilizing denaturing gradient gel electrophoresis and direct sequencing as
analytical tools (Cariello et al., 1988). Deletions primarily of exon 2 and 3 were identified by
McGinniss et al (1989) in their analysis of in vivo hprt mutations in human new bom T-
lymphocytes (McGinniss et al., 1989)  A study by Recio et al., (1990) of spontaneous in vivo
hprt mutations in human T-lymphocytes identified single base substitutions, insertions, small
deletions and large deletions of entire exons. The large deletions suggested mutations in hprt
sequences that regulate splicing of hprt mRNA. The growing amount of scientific data on
hprt is significant. Currently a data base is being compiled of all mutations at hprt produced
by chemicals and physical agents in a wide variety of model systems (Cariello et al., 1992).
The truly unique capability of the cell line used in this study is their ability to express
cytochrome P450nEl activity. Most mamalian cell lines used in mutation studies lack the
ability to metabolize xenobiotic compounds and convert them to their mutagenic form. To
circumvent this deficiency, some form of exogeneous activating enzymes must also be
provided to metabolize promutagenic chemicals to their active form. This limitation also
demands that the metabolites are produced outside of the plasma membrane and must be
transported across to interact with the genetic target (Gonzalez et al., 1991).
Since cell lines can be stably transfected with extrachromosonal vectors, the
opportunity exists to transform the cells with cloned P450 activity needed to metabolize the
compounds of interest (Gonzalez et al., 1991). The AHH-1 cell line have within their
genome, an integrated Epstein Barr Virus (EBV) genome. Epstein-Barr Virus (EBV) is
22
responsible for the immortalization of the cell line and is necessary for the cells' continued
propagation in culture. The cytochrome introduced extrachromosomally into AHH-1 cells, is
IIEl (Gonzalez, 1991). This P450 is capable of oxidizing many compounds including VCM
(Guengerrich et al., 1991). The vector used to transfect the cDNA with P450nEl in this cell
line was pEBVHistk.   This vector contains the origin of replication (P element) of EBV and
allows replication of the extrachromosomal plasmid carrying the P450nEl cDNAs (Sugden
et al., 1985 and Yates et al., 1984). The selectable marker in the vector is the Escherichia
coli HisD (histidinol dehydrogenase) gene which confers resistance to 1-histidinol.
Histidinol is a potent protein synthesis inhibitor. Histidinol dehydrogenase can convert the
histidinol present in the cell to the essential (and non-toxic) amino acid L - histidine. Cells
that have lost all copies of the extrachromosomal vector (or have lost enough copies so there
is not sufficient histidinol dehydrogenase activity present to convert the histidinol) will not
survive. Therefore, maintaining cells in media containing 1- histidinol provides adequate
selective pressure to ensure cells in culture contain the transfected plasmid and thus the
desired cytochrome P450nEl enzymatic capabihty (Crespi,1990). Constant selection
maintains approximately 40 extrachromosomal copies per cell. This methodology of
selection in mammalian cell culture was originally reported by Hartman (Hartman et al.,
1988).
Since induction of the cytochrome P450nEl is not possible in these cells, the level of
metabolic activity is determined by the plasmid copy number per ceU. This vector is stable
(in the presence of the selective agent) for at least 70 days of cell culture (Gonzalez, 1991).
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A final important aspect of the cell line is its lack of microsomal epoxide hydrolase
activity (Crespi, 1990). One would expect that epoxide hydrolase activity near the
cytochrome P450 system would catalyze the detoxification of CEO and essentially abolish
the alkylating ability of CEO (Guengerich, et al., 1979 and Amdur et al., 1986).
Toxicitv
Defining toxicity at the cellular level is less complicated than for an entire organism,
but is still not trivial. Toxic effects in a cell can be observed at many levels, with cell death
being the most easy to identify. Toxicity at the cellular level can also include growth delays
due to destruction of intracellular macromolecules, alterations in metabolic processes,
changes in cellular or nuclear membranes, disruption of the cells replicative cycle, or
interactions with proteins, DNA, and RNA and the processes responsible for synthesis and
repair of these cellular molecules (Grisham, 1984).
Observations of toxic effects in human cellular systems provide little information on
the ultimate toxic effect in humans. However, it is an important and useful parameter to
measure in cell systems. First, within a given cell system, it can be used to measure the
relative reactivity of closely related test compounds (such as in the present study). More
importantly, toxicity determinations are a necessary element in demonstrating that mutation
experiments are correctly carried out and contain statistically significant number of surviving
mutants. For many chemicals analyzed in human cellular test systems, the toxicity of the
compound can limit the dose concentrations that can be tested. In their statistical analysis of
human lymphoblast mutation assays. Penman and Crespi determined that the relative survival
after exposure should be between 10 and 30%. Maintaining a large number of surviving
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mutants after exposure serves to decrease the variability between repeat experiments and
increases the sensitivity of the protocol (Penman and Crespi, 1987, and Gentest, 1990).
There are two factors which can be altered to ensure that enough mutant cells are present in
culture after treatment; one is to treat a higher concentration (or total number) of cells, and
the other is to ensure the level of toxicity is within the range mentioned previously. An
example will more clearly represent the importance of maintaining the specified range of
toxicity in the experimental design: if 3x10' cells total are treated in culture and the
mutation frequency is 3x10'  and there is no measureable toxicity, then there will be 90 total
mutants in the cell population after treatment (3x10' x 3x10'"), with a standard deviation of
the mutants of about 10%. However, if in the same treatment, the relative survival was only
10%, then there would be only 9 mutants total with a 33% standard deviation (from Gentest,
1990). Additionally, careful consideration of the number of surviving mutants is also critical
in obtaining mutational spectra (as in the present study). In the latter example, the mutant
population analyzed would have been the progeny of only nine different cells, and the
analysis of the resultant spectra would have limited significance.
Quantification of cellular toxicity from exposure to VCM, CAA, and CEO is an
important aspect of this study. Trypan blue exclusion observed through microscopic
examination has been determined to be an un-reliable measure of toxicity in general, and
most definitely not a good measure of toxicity for the AHH-1 cell line used in this study
(Grisham, 1984 and Gentest, 1990). Trypan blue only measures plasma membrane
breaching, and as discussed above, there are more subtle ways in which a cell can be killed.
The primary technique used in this study to measure toxicity of VCM, CAA, and CEO
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exposures is through the determination of relative macroscopic colony forming ability or
plating efficiency (PE) in 96 well microtiter plates. The plating assay is based on the abiUty
of the plated cells to survive treatment and progress through a sufficient number of cycles in
a given tin^ period to be visible for counting (scoring). The length of time required for
colonies to become visible varies between different cell lines. Fifteen days incubation time
has proven to be sufficient for the cell line used in this study.
Another measure of cellular toxicity is growth delay. Cells are counted each day after
treatment and the length of time prior to the resumption of logarithmic growth with normal
doubling time is determined. This growth delay time may be due to inhibition of cell growth
due to the exposure, or to actual cell kilUng. In the latter case the growth lag time results
from the time required by the small number of Uving cells to repopulate the culture.
Comparison of growth delay and PE can distinguish between the two possibilities.
Control populations of untreated cells are a crucial part of the study. Even untreated
cells do not form colonies at 100% efficiency. For this reason, untreated, control cells which
were handled in a manner identical to the treated cells (less the chemical exposure) are used
as comparison when the weU count data is processed to ascertain the level of toxicity. The
distribution of colony forming units (CPU's) is across a large number of possible locations
(96 wells on a single microtiter plate), and is expected to follow the Poission distribution
(Furth et. al., 1981). Because of this distribution, it is possible to calculate the average
number of CPU's that were distributed to the 96 wells by observing the number of positive
and negative wells. According to Poission statistics, the fraction of negative wells P(0) is
equal to e'"^, where m is the average CPU's per well. Consequently, m = -ln[P(0)]. Cells are
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plated for toxicity at limiting cell density such that both positive and negative wells are seen.
The plating efficiency (PE) of a culture can be calculated as:
PE = CPU per well/number of cells per well
The number of cells per well is based on physical cell counts and the preparation of known
dilutions.  The PE calculated for the zero treatment controls can be compared to the PE
obtained for different levels of exposure and a percent relative survival can be calculated :
Relative Survival = PE treated cultures/PE controls
Consequently a culture displaying the same PE as the control has a relative survival (RS) of
1.0; cultures with a lower PE have a RS <1.0.   For the cells used in this protocol, average
values for PE ranged from 30%-60%. This methodology provides a quantitative measure of
toxicity in the cells at different levels of exposure to VCM and its metabolites.
Mutagenicity
The plating efficiency of a culture in the presence of 6TG can also be determined in the same
fashion described in the previous section. Of course, the resultant colonies are 6TG^, hprt"
mutants. To convert the PE of the culture in the presence of 6TG to actual mutation
frequency, the 6TG PE is divided by the PE of the culture in the absence of 6TG:
MF = PE in 6TG/PE without 6TG
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Fig 2.1.  The HPRT metabolic pathway. This diagram illustrates the two selection
mechanisms for both hprt"*" and hprt" phenotypes used in this study.
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Polymerase Chain Reaction
The practical analysis of mutations in defined regions of DNA has been made possible
through the advent of the polymerase chain reaction (PCR). PCR is an in vitro method for
the amplification of defined DNA sequences. Two oligonucleotide primers are used that
hybridize to the regions on the DNA flanking the section to be amplified (Erlich, 1989). The
flanking sequences of the target DNA must be known in detail so that primers can be
designed to anneal specifically at those regions. In general, the reaction mixture consists of
DNA (which does not need to be purified but only include the desired sequence to be
copied), an excess of the two primers, the four different deoxyribonucleoside triphosphates,
and DNA polymerase (MuUis, 1987). This reaction mixture is subjected to a specified
number of thermal cycles, each of which consists of a high temperature melting step to
denature the DNA (94-96' C), a lower temperature, primer-annealing step (42-47' C)
followed by an intermediate extending step (72 * C) where the deoxyribonucleosides are
incorporated into a "new" strand of DNA by polymerase. The reaction produces an
exponentially increasing number of dsDNA molecules of the length defined by the two
primers (MuUis, 1987). A significant improvement in the PCR process was the discovery of
a thermostable DNA polymerase isolated from Thermus aquaticm bacteria (Taq) by
Gefland and Stoffel. The use of Taq as the DNA polymerase has resulted in an automated
PCR process, since Taq polymerase can withstand the high temperatures needed to denature
the DNA and therefore does not have to be added at each cycle.   Additionally, since Taq also
has a higher optimized temperature, higher annealing and extending temperatures can be
used. This increases the stringency of the reaction and minimizes production of strands
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resulting from primer annealing at incorrect locations (Saki, 1988, and Rychilik, 1990). PCR
also allows the incorporation of new base pairs at the ends of amplified molecules through
the construction of primers containing the new sequences. This is possible because
mismatches between the 5' end of the oligonucleotide primer and the initial flanking regions
of DNA are tolerated in the PCR reaction and the production of new strands of specified
DNA become incorporated into all subsequent copies produced. After several cycles, the
vast majority of product contains the entire primer sequence, including the added base pairs
(Erlich, 1989). This aspect of PCR is exploited for the analysis of mutant DNA by allowing
the incorporation of sections rich in G-C pairs (G-C clamps) and the incorporation of bases
that act as recognition sequences for the fluorescent sequencing primers; both of which will
be discussed in the following sections.
Denaturing Gradient Gel Electrophoresis
Denaturing gradient gel electrophoresis (DGGE) allows the resolution of DNA
fragments that differ in sequence by as little as a single base pair (Fisher and Lerman, 1983).
This procedure can translate a minor difference in sequence into significant differences in
position on a polyacylamide denaturing gel (Lerman, 1986). These separations are brought
about by differences in melting temperatures (Tm) of DNA, which is criticallly dependent on
the DNA sequence.   Melting of the DNA is defined as an "equilibrium between two well-
defined states for each base pair - that of the double helix and that of a more nearly random
chain in which bases are neither paired nor stacked on adjacent bases in an orderly way"
(Myers et al., 1987). Describing melting domains based on their temperature is analogous to
describing the same domain based on the effects of the denaturant concentration used in the
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DGGE system (urea and formamide) (Myers et al., 1987). The DNA melts in discrete
segments or domain of 25 to several hundred base pairs in length, and for each domain the
melting is cooperative across the domain, at the Tm (Erlich, 1989). These domains are
clearly demarcated from one another and a base pair change in one domain, affecting its
melting temperature, will usually have little or no effect on the surrounding domain(s)
(Myers et al., 1987). In exon three of human hprt, there are two well defined domains. The
low temperature melting domain is located from base pair 214-319, of exon 3, while the
high-temperature domain is bp 135-213.
The central principle of DGGE is that DNA molecules that are partly helical and partly
melted (caused by the melting of a single domain) will migrate at a much slower rate in a
polyacrylamide gel than the fully helical molecule and the rate will decrease more as the
melted portion increases (Lerman, 1986).   In practice, a DNA fragment migrates through a
polyacrylamide gel that contains a linear gradient concentration, increasing from top to
bottom. As the DNA reaches the denaturant concentration where the lowest melting domain
denatures (Tm) the DNA is in a partly melted, partly helical state and its mobility is greatly
decreased (Erlich, 1989). Staining of the DNA with ethidium bromide or labeling with
radioactivity permits the location of the DNA band to be determined.
In its unmodified form, DGGE is only partly successful in separation of all mutants in a
DNA fragment of interest. This is due to the fact that DGGE cannot separate fragments
where the base pair changes are in the highest melting domain since the mobility of the DNA
has already been gready reduced when the low temperature domain separated, and melting of
the higher domain has essentially no significant effect on the reduction of mobility (Myers et
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al., 1985).   To overcome the inherent inability to resolve mutants in the high temperature
melting domain, the melting characteristics of the DNA fragment can be altered through the
attachment of a length of nucleotides rich in guanine and cytosine. This attached sequence is
termed a GC clamp (Myers et al, 1985a). With a GC-clamp, the entire fragment of interest
can be melted as it passes through the denaturant, but the GC clamp remains duplexed. This
significant alteration in the melting temperature of the molecule was hypothesized to enable
detections of base changes in all melting domains of a DNA fragment (Myers et al., 1985b).
In the first studies with this procedure (in the jj-globin promoter fragment) the fi-action of all
substitution that could be detected by DGGE increased from 40 to 95% with the addition of a
GC clamp (Myers et al., 1985b). The first clamps utilized in these studies were long (300bp)
and were not 100% G+C. It was later determined that a 100% G+C clamp of only 40 base
pairs was needed to resolve base substitutions in all of the melting domains of DNA fragment
(Sheffield etal., 1989).
The process of altering the melting temperature of a DNA fragment through the clamp,
was combined with PCR technology as the means to attach the clamped fragment. This
technique increased the ability to detect most base substitutions in all of the melting domains
from a very small quantity of initial, undamped fragment as the starting template (Sheffield
et al., 1989). This meant that DGGE technology could be used to detect mutations in human
genomic DNA from a starting point of less than 5 ng of DNA (Sheffield et al., 1989).
Heteroduplex DNA, in which there is a mismatch at a single base, always migrates at a
much slower rate than either the mutant:mutant or wild-type homoduplexes. This
phenomenon is attributed to the destabilizing effects of the mismatch (Myers et al., 1985).
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The use of heteroduplex DNA in DGGE analysis is advantageous since their physical
separation on the gel from the wild type homoduplex is always greater than that of mutant
homoduplexes. This allows for the identification of mutants in cases where the mutant
homoduplex does not resolve from the wild-type homoduplex (Erlich, 1989). To form
heteroduplexes, mutant and wild-type homoduplexes are denatured and allowed to reanneal.
Heteroduplex formation insures the resolution of all mutants in the denaturing gel.
The ability of DGGE to distinguish mutant DNA from wild-type DNA is limited by
fidelity of the DNA polymerase used in the PCR reactions. Cariello et al., (1990) analysed
complex human cell populations containing mutants induced by the alkylating agent MNNG
or the intercalating agent ICR-191. In the study they determined that mutants comprising at
least one percent of the total population of cells can be distingushed from wild type DNA as a
distinct band or set of bands on a denaturing gradient gel. If the mutant population was less
than one percent, the background noise on the gel (visuaUzed by a smear) caused by DNA
polymerase infidelity would prevent the identification of unique bands (Cariello et al., 1990).
In this present study, all mutants analyzed are hprt", but not all mutations reside in
exon 3, the target of study. We are concentrating on exon 3 since this is the only exon which
can be examined in the in vivo mouse model in our laboratory. Also, exon 3 contains 28% of
the coding frame in a continuous length and is the exon believed to code for both catalytic
sites of the enzyme (Wilson et al., 1983). EXjGE analysis of DNA is used to 1) identify
mutants with mutations in exon 3 and 2) purify mutant from wild type DNA (Cariello, et al.,
1990).
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Automated DNA Sequencing
Sequencing of the amplified mutant DNA is the analytical endpoint for mutants that
resolved as unique bands on the denaturing gradient gel. Direct visual comparison of the
mutant sequence with the wild type sequence will indicate the exact nature and location of
the mutation. The frequency of occurrence of each of the mutations is calculated and a
mutational spectrum with mutational "hot spots" constructed.
The automated sequencing is based on the dideoxy termination method of DNA
sequencing. In this enzymatic approach, ssDNA template is copied by a polymerase using a
specific primer. The reactions are carried out in four separate tubes, each containing ssDNA
template, primer, dNTP's and a small amount of a specific dideoxy nucleotide (lacking the
3'-OH). A different dideoxy is added to each of the four reaction mixtures. Incorporation of
the dideoxy nucleotide into the elongating dsDNA causes termination at the base specified by
the dideoxy ribose.   Each of the four reaction tubes will contain varying lengths of DNA and
in a given tube all DNA molecules will end in the same dideoxy nucleotide (Lewin, 1990).
When the samples are run on a denaturing polyacrylamide gel, the DNA size-fractionates and
the sequence pattern can be read horizontally across the gel with the next base in the
sequence always indicated by the next higher band in the gel. In the automated sequencing
procedure, four different fluorescent primers, each with a unique signal, are used in the four
dideoxy reactions.   The Applied Biosystems Incorporated model 370a DNA sequencer was
used for electrophoresis and detection of sequence data after seqencing reactions were
prepared stringently following ABI's recommended protocol. The four different dyes are
detected by laser activated fluorescence. Photomultipliers with four color filters collect data
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in real time near the bottom of the gel as the data is stored in computer memory for further
evaluation.
CHAPTER IV
TOXICIY AND MUTAGENICITY
OF
VCM, CEO, AND CAA
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MATERIALS AND METHODS
An overview in the form of a flow chart of the mutation assays done for this study is
provided in figure 4.1.
Chemicals, Enzymes and Media Compounds:
Materials for the toxicity and mutation assays were obtained from the following
sources: RPMI 1640 (Ix with L-glutamine), Dulbecco's phosphate buffered saline (PBS) pH
7.5, 8.0 mg/ml NaCl, 0.2 mg/ml KCl, 1.15 mg/ml Na2Hpo4, and 0.2 mg/ml KH2PO4 and
penicillin and streptomycin (lOOOx) were obtained from Lineberger Cancer Research Center,
Tissue Culture Facility. L-glutamine; 200mM as 29.2 mg/ml in 0.85M NaCl were from
Gibco, Life Technologies Grand Island, NY. Bovine Calf Serum, Lots 21512008 and
21511064, from HyClone Laboratories, Logan UT. Aminopterin, hypoxanthine (6-
hydroxypurine), thymidine (l-[2-deoxy a-D-ribofuranosyl]-5-methyl uracil) 99-100%,
deoxycytidine, 6-thioguanine - (2 amino-6-mercaptopurine) 98%, and L-histidinol were
purchased from Sigma Chemical Company, St. Louis, MO. Vinyl chloride and ethylene
oxide (>99.5%) were obtained from Fluka Chemica, Switzerland. CAA was obtained as a
50% w/w solution in H2O from Aldrich Chemical Company, Milwaukee WI. CEO was
synthesized by Dr. Avram Gold, Department of Environmental Sciences and Engineering,
University of North CaroUna, Chapel Hill, NC. through photochemical chlorination of
ethylene oxide in the prescence of tertiary butyl hypochlorite (Walling and Fredricks, 1962).
The t-butyl hypochlorite was a generous gift of Dr. Amamath, Department of Pathology,
Duke University, Durham, NC. The AHH-1 IIEl cell line were the generous gift of Gentest
Corporation, 6 Henshaw St., Wobum Ma.
38
Safety Considerations
Safety in handling chemical carcinogens, selective agents, and the cells in culture was
always paramount in experimental design.
The cell line used in this study contains Epstein Barr Virus DNA which necessitates
the handling in accordance with NIH guidelines for research with recombinant DNA
molecules (Gentest 90-1). EBV transfected cells do have the potential to shed the active
virus, although this is highly unlikely. All regular cell culture work was accomplished in a
Health and Safety certified biological safety hood with vertical laminar an- flow and extemal
exhaust. In addition, latex gloves and a laboratory coat were worn when handling cells in
culture. The selective agents aminopterin and 6TG are both toxic compounds and were
handled in the biological safety hood only after they were placed in solution. Solutions of
these compounds were prepared in an approved chemical laboratory hood.
The exposures to VCM, CAA, and CEO were all accomplished in a chemical lab
hood. In addition, a NIOSH approved, fit-tested, half-face respirator with organic vapor
cartridges (TC-23c-435) was worn. The cartridges were replaced frequendy (every 2-3
weeks) to preclude cartridge saturation and breakthrough. The use of vinyl chloride in the
workplace is federally regulated under OSHA Standard 1910.1017. These regulations were
implemented where applicable. During treatment with any of the three compounds, the door
to the room was closed and a sign posted that warned others that vinyl chloride, a cancer
suspect agent, was in use. An incubator was dedicated solely for use during the cell
exposures and was appropriately labeled during the exposure period. In addition to its
carcinogenic properties, vinyl chloride is an extremely flammable gas and is maintained
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under pressure. Consequendy, the compound was handled very cautiously when it was in the
gaseous state and all sources of ignition were removed form the hood. When the stock gas
cylinder was not in use, it was stored inside the chemical lab hood. All contaminated media
and disposable plasticware were kept in the chemical laboratory hood until it was packaged
for disposal through the Health and Safety office. Material safety data sheets for the
compounds used were available in the work area to provide additional safety guidelines.
Cell Culture
The stocks were maintained at -70' C in DMSO until ready for use.   Cells were
quickly thawed at 37 * C, diluted in 50 ml of prewarmed RPMI 1640,10% bovine calf senim
without antibiotics (stock media), pelleted with centrifugation (lOOOg 3 min) and
resuspended in 50 ml of stock media. The cytoprotective agent, DMSO inhibits cytochrome
P450IIE1 activity and must be removed from the media (Yoo et al., 1987).   Selective
pressure for the IIEl plasmid is begun immediately after resuspending the cell pellet in fresh
media and is accomplished by the addition of 3mM L-histidinol. L-histidinol was stored as
300x stock in 0.500 ml aliquots in cryogenic vials at -20' C and thawed individually.
(Repeated freezing and thawing of L-histidinol in solution (sterile PBS) is not appropriate
according to the technical department of Sigma Chemical Company.) 7.5%NaHC03 was
added 0.250 ml/ 50 ml whenever L-histidinol was added to buffer the alkalinity of histidinol.
Histidinol was added to the cell culture after each dilution (three days per week) up through
the treatment with HAT. Cells were maintained in a 37 ° C incubator with 6% CO2,100%
humidity in 75 cm  sterile tissue culture flasks. Cells were enumerated approximately every
other day using a Coulter Counter (Coulter Electronics, Hialeah FI.) and diluted using
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prewarmed (37 * C stock media) to a concentration of 0.5 - 4.0 x 10^ cells/ml. Cells were
never grown at cell concentrations exceeding 1.2x10 cells/ml. Cell cultures were tested
periodically and found negative for mycoplasma contamination. Cell doubling time was
calculated periodically using the formula:
r = [ln2(T)]/[ln(N/No)
Where t is the doubling time in hours, T the difference in hours between the time the cells
were last diluted and the current cell count, N is the current cell concentration (cells/ml) and
N_ is the cell concentration when the cells were last counted. Average doubling time for this
cell line is 22 hours; longer doubling times (in excess of 30 hours) were viewed as suspect for
possible culturing problems. Cell culture was maintained during and after treatment as
described, but the cultures were supplemented with penicillin (100 units/ml) and
streptomycin (100 ng/ml).
Pretreatment of cell stocks in HAT media to reduce the level of background mutants
was carried out prior to each exposure to the test substance. The HAT treatment consisted of
2x10    M hypoxanthine, 8x10"' M aminopterin and 3.5x10"^ M thymidine. Stock media
was used through HAT treatment. HAT was prepared as 333x HT in 0.3N HCl, 0.2 nm filter
sterilized and 250x A in 0. IN NaOH, 0.2 fim filter sterilized and stored at -20' C in a frost-
free freezer. HAT treatment was carried out for 72 hours while maintaining exponential
growth. Histidinol selection was maintained through the HAT treatment. All cells which
were used in any one experiment (cells for controls and treated cultures) were passaged
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through the HAT treatment in a single culture. Cells were counted and diluted after 48 hours
and the HAT concentrations re-established for an additional 24 hours. Cells were then
centrifuged in an lEC Centra 8 table top centrifuge for three minutes at 1000 rpm, 25 * C.
The supernatant was carefully removed and the cell pellet resuspended in pre-warmed stock
media, and HT (no aminopterin) added in the same concentrations as in the HAT treatment
for recovery. Cells were allowed to grow for two to three days after the 24 hour recovery in
HT to achieve adequate cell numbers for treatments. Treatments were accomplished in 50 ml
cell suspension, (4xl0^/ml) in 75 cm"^ tissue culture flasks for 24 hours. The media used was
RPMI1640,10% BCS with penicillin and streptomycin (referred to as treatment media).
During treatment, flasks were sealed to prevent carcinogen contamination of the atmosphere
in the incubator. While sealed, the CO2 in the incubator could not reach the media to
maintain pH; therefore the treatment media was supplemented with 29 mM HEPES buffer
during the 24 hour treatment period. After treatment, the entire volume of cells or a fraction
thereof (depending on whether toxicity was anticipated or not) was pelleted, resuspended in
fifteen ml prewarmed treatment media in a 50 ml centrifuge tube, pelleted again and
resuspended in 50 ml of treatment media in 75 cm"^ flasks. The cell density was determined
and two plates were seeded per treatment concentration for toxicity determination. The time
at which this initial density was determined was the starting point for evaluating growth
delay. The counts from the two plates were pooled to calculate PE. Cells were carried for
six days to allow phenotypic expression at the hprt phenotype; during this time the cell
cultures were diluted daily to 4x10^ cells/ml. Cell density was ascertained on day seven and
the cells were plated for mutant fraction as described previously. Replicate plates (2 -10
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depending on the treatment and anticipated MF) were used for each treatment and the counts
of all the plates were pooled to calculate the MF. Three independent cultures were exposed
and carried through MF determination for each concentration of compound tested. Actual
number of flasks (and consequently number of cells) initially treated varied according to
toxicity. Four control flasks were maintained in every experiment.
Plating
Cells at a determined density were plated in 96-well, flat bottom microliter plates (well
capacity 0.35 ml, surface area of 0.28 cm , Costar Corp). The volurrw plated per well was
0.2 ml in all cases. The media used for plating was RPMI1640 plus 15% bovine calf serum,
IX penicillin and streptomycin, and 1.0 mM L-glutamine. Plates were maintained
undisturbed in a water jacket incubator at 6% CO2 for 15 days before colonies were scored.
Because of the ability of this cell line to form rather large colonies (2 mm in diameter and
larger, both mutant colonies and wild type) the plates were scored by counting colonies from
the back side of the plate without magnification. Contaminated or empty wells were
excluded from the calculation to determine plating efficiency or mutant fraction. Plating
efficiencies ranged from 20-60%. Cells for the purpose of determining toxicity or plating
efficiency were plated at a density of two cells per well. The only exception was in plating
cells after exposure to higher doses of CAA where toxicity required that four cells/well
(16mM exposure) and 30 cells/well (24 mM exposure) be plated. To determine the frequency
of hprt" mutants generated by exposure to the test substances, cells were plated at an
optimized concentration of 30,000 cells per well in the presence of 1 ug/ml of the selective
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agent 6-thioguanine (6TG). Plating efficiencies (PE) and mutant fraction (MF) were
calculated as described previously.
Determination of Treatment Concentrations
Initial cytotoxicity studies were accomplished with the three compounds over a broad
range of test substance concentrations. Ten milliliter cultures at 4x10-^ cells/ml in 25 cm''
sterile tissue culture flasks were used. Preliminary results from the VCM toxicity and
mutagenicity experiments indicated that 24 hour treatments would be preferable versus
shorter periods due to the limited response seen. Therefore, for consistency, all cell
exposures were conducted for 24 hours. The preliminary results from the VCM studies
indicated that VCM solubility would determine the upper treatment concentration. This level
was determined as 500mM. Dose ranges of 8-24/xM for CAA and 25-75 mM for CEO were
selected; the upper level of these doses approached 10% survival.
When the first mutation determinations were made, a very high background MF was
observed, (9 - 75 x 10""). High background levels of mutants can be due to: artifacts from
low plating efficiencies, improper aminopterin concentrations, exposure to some other
mutagen, or an inadequate selective agent (6TG) (Gentest, 1990). These possibilities were
tested and eliminated. We then demonstrated that the high background was dominated by an
unusual 6TG^, HAT^ population. Although never tested, it was assumed that this was an
hprt" mutant lacking activity with 6TG but retaining sufficient activity with hj^oxanthine to
permit growth in HAT. To obtain cultures free of this mutant, ten milliliter cultures with 10
cells total were established. After cultures were grown to a concentration of 10" cells/ml, the
cells were plated for MF. The rest of the cell stock was frozen. Plates were scored after
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fifteen days incubation. Cultures with very low background MF (3 x 10'   or less) were
considered to be mutant free and aliquots cryo-preserved. These "mutant free" cell stocks
were then used for all mutation assays.
VCM Treatment
Liquid VCM was prepared by carefully releasing gaseous VCM through tygon tubing
into a small-necked glass scintillation vial submerged in a dry ice/acetone bath (-70 * C) in a
chemical laboratory hood. The liquid VCM was quickly transferred to a dry ice/ acetone
cooled 20 ml amber serum vial containing 10 ml MeOH. The bottle was quickly capped with
a septum and the septum locked into place with an aluminum collar. The weight of the bottle
and contents was determined and the amount of VCM collected was calculated by subtracting
the weight of the bottle, septum, collar, and MeOH. From this, the VCM/MeOH ratio could
be established.   The VCM/MeOH stock was maintained on dry ice/acetone until needed for
preparing the dosing solutions. The final concentration of the VCM stock used to treat the
cultures was a compromise between two critical factors. The final MeOH concentration in
the culture had to be kept below 0.03% to avoid inhibition of the cytochrome P450nEl
activity (Gentest, 1990). This demanded a high VCM/MeOH ratio in the stock. However,
the MeOH concentration had to be high enough to ensure VCM solubility. Treatment
solutions (lOmM, 25mM, and 50mM) were prepared from the VCM/MeOH immediately
prior to treatment by diluting the VCM/MeOH into cold unsupplemented RPMI1640, with
an ice-cold gas-tight Hamilton syringe. Concentrations of treatment solutions were selected
to permit volumes delivered to treated cultures to remain between 0.1 ml and 0.5 ml, a
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volume accurately delivered with a Ice tuberculin syringe.   Treatment flasks contained 50
ml of 4x10^ cells/ml. Flasks were sealed with sterile rubber septum stoppers which were
sealed with vinyl tape. VCM/MeOH stocks and treatment solutions were maintained as cold
as possible during transfers. Vials containing these solutions were kept in dry ice/acetone
(stock solutions) or near freezing on dry ice (treatment solutions). Appropriate volumes of
treatment solution were measured in a syringe by holding the syringe against dry ice as the
solution was drawn into it.   Doses delivered into the treatment flasks were always injected
through the cell suspension with the opening of the treatment flask pointing down and the
mixture gently agitated before setting the flask down. This arrangement ensured: 1) efficient
delivery of the treatment solutions with minimal losses, 2) the delivered dose remained in the
tissue culture flask (in solution or in the head space) 3) no contamination of either the
incubator or the laboratory with VCM. After treatment, the rubber septums were cut off and
held for appropriate disposal. Three cultures were treated for each exposure concentration
and three MF plates were prepared from each culture (nine plates for each dose). Two MF
plates were prepared for each control culture and two plates for each treatment concentration
for both PE and toxicity plates. Two consecutive treatments were accomplished at 300 and
500 mM to induce greater mutant fractions and allow for the collection of mutants for
analysis. Since VCM toxicity was never observed, the second treatment was administered
the same day the cells were removed form the first treatment.
CAA Treatment
CAA treatment stock was prepared as 100 mM in PBS. This was diluted to 1 mM in
unsupplemented RPMI. The 1 mM stock was used for all cell treatments. New CAA stock
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was prepared from the purchased CAA stock for each treatment The 1 mM stock was added
to 50 ml cultures at 4.5x10^ cells/ml at a final concentration of 8,16, or 24 nM. Cultures
were tightly capped, gently mixed and placed in the 37' C incubator for 24 hours. Controls
were also capped tightly and contained HEPES buffer at the same concentration. Four
replicate control cultures, three replicate cultures at 8 pM, 6 cultures at 16/iM, and 15
cultures at 24 mM were treated.   After growth resumed in the flasks, the 16 and 24 nM
treatments were pooled into three cultures. When cells were plated for MF, there was a total
of three cultures for each treatment concentration and four controls.
The following number of plates were used for each treatment concentration to
determine MF: two plates per each of the three treatment cultures for S/iM, six plates per
each of the three pooled treatment cultures at 16mM and ten plates for each of the three
pooled treatment cultures at 24mM. Two plates for each control were plated. To obtain cells
for DGGE analysis, two consecutive treatments were carried out at 16mM; the second
treatment started after the cells had recovered from the first treatment (i.e. log growth with
approximately 22 hour doubling times). Attempts were made for bulk selection of mutants in
large spinner cultures (900 ml, 4x10^ cells/ml - 1.0x10" cells/ml in 1 liter jars on a magnetic
stir plate) (Carriello et al.,1991). However, the combined effects of toxicity from the CAA
exposure and the propensity to grow poorly in bulk spinner cultures (Gentest, 1990) resulted
in forgoing this method of isolating mutants for analysis.
CEO Exposure
CEO density was determined by weight using a Mettler AE240 analytical balance to be
1.102 gm/ml. CEO purity was determined as 97% for the first three treatments, and 85% for
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the fourth treatntent. Purity was determined based on nuclear magnetic resonance (NMR)
recorded at the time of synthesis. CEO treatment stocks were prepared in acetone from the
pure CEO immediately before treatment. The appropriate volume of acetone for treatment
solutions was aliquoted into 20ml amber serum vials and kept covered in dry ice/acetone.
The CEO was quickly thawed, the volume of CEO needed removed with a pipette, and
delivered to the serum botde which was then sealed with a rubber septum and collar. The
CEO was quickly returned to the dry ice acetone and cell cultures were treated as described
fortheVCM. Treatments of 100mM,75mM, 50/iM and 25mM were conducted. CEO was
delivered in acetone at a final level of 0.04% in each culture including controls, (acetone
produces signs of toxicity in these cells at 0.5% (Gentest, 1990). Triplicate cultures were
treated at each dosing concentration and ultimately three MF plates were prepared from each
treatment flask (nine plates per treatment dose).
RESULTS
Toxicitv
The plating efficiency of treated cultures immediately after treatment was compared to
that of controls and expressed as relative survival. CAA and CEO showed a dose-dependent
decrease in survival following treatment (Fig 4.2) and (Fig 4.3) respectively. On a molar
basis, CAA was much more toxic than CEO. No toxicity was observed at any of the VCM
concentrations tested (Fig 4.4). Therefore, the toxicity induced by the three compounds can
be compared on a molar basis and represented as: CAA>CEO»VCM.
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Growth Delay
After treatment the cells were monitored by daily counts. As an example of culture
growth following treatment, results obtained with one CAA experiment (the compound that
showed the greatest level of toxicity) are provided in Fig 4.5. There was a dose-dependent
increase in growth delay from treatment with CAA. One can extrapolate the linear portion of
the curves (in Fig 4.5) back to t=o to obtain the theoretical number of surviving cells required
to produce the exponential growth eventually observed in the culture. For example, estimates
with 24 mM indicate that at least 1% of treated cells had to survive to produce the observed
growth. This value is very close to actual cell survival determined by plating. Therefore, the
delay in culture growth was due mainly to cell killing and not to delay in cell cycling.
Mutant Fraction
The average induced hprt" mutant fraction (observed MF minus concurrent control
MF) for the three different treatments was determined (Fig 4.6-4.8). For the VCM exposures,
each point represents the average of from 3-5 independent experiments. For CEO treatments,
each value is the average of four independent experiments and for CAA every value is the
average of three experiments. In turn, the determination in each experiment is the average of
3 independent test cultures.   Error bars are standard error of the mean based on the number
of studies accomplished at each treatment concentration. The background mutant fraction
varied for each study with each compound, and the ranges of background M.F. (xlO" ) were
2.1 - 5.6 for VCM, 3.8 - 5.6 for CAA, and 2.1 - 10.8 for CEO.   The use of induced mutant
fraction allows for comparison between independent experiments with different background
MF. On a molar basis, CEO is very similar to CAA in terms of mutagenic potential. The
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induced mutant fraction with each compound increased in a linear fashion with increasing
concentraion. However, as discussed above the two compounds differ greatly in terms of
toxicity. Consequently, at equi-mutagenic concentrations, CAA is much more toxic than
CEO. VCM consistently produced a MF above background level, but a monotonically-
increasing response was not observed.
DISCUSSION
We have used the human cell line AHH-1 which expressed cytochrome P450IIE1
activity to test the mutagenic potency of vinyl chloride and its metabolic products,
chloroethylene oxide, and chloroacetaldehyde. VCM requires metabolic activation through
cytochrome P450nEl to exhibit its mutagenic and toxic effects. Both CEO and CAA can
react with nucleophilic cellular macromolecules, including DNA and can form stable DNA
adducts. These adducts, if unrepaired or repaired incorrectly can result in heritable DNA
damage.
The concentration-dependence of the VCM results suggest a plateau of mutagenic
response, which one would anticipate from the saturation of metaboUc activation of VCM.
No toxicity was seen at any of the concentrations tested. Substantial flucuation in measured
MF was seen and can be attributed to the difficulty in delivering VCM reproducibly to the
treatment flasks and the fact that induced levels were not large compared to background
levels. Also, a simple monotonically-increasing response is not apparent. This may be the
result of varying two competing parameters in the study: 1) VCM concentrations which will
affect the final mutation frequency and 2) methanol concentrations which can affect the
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ability of P450 to activate VCM. Methanol concentrations of only 0.03% will have an
impact on the metabolizing capabilities of the cell line (Gentest, 1990). This is plausible,
since repUcate experiments with different MeOH concentrations showed a consistent
modualtion of VCM mutagenesis as a fraction of MeOH concentration.   In comparing
mutant fraction induced at the same delivered dose of VCM, the higher mutant fraction
usually occured at a lower MeOH concentration. The data would indicate that in an attempt
to ensure delivery of the measured dose, by avoiding VCM loss from VCM coming out of
solution, the MeOH concentration contributed to the ineffectiveness of the metabolic system
to oxidize VCM to CEO.
The values in Fig 4.8 represent the theoretical delivered dose to the flasks. Due to the
volatility of VCM, one expects a certain fraction to escape from the medium and reside in the
flask head space during treatment. Therefore the values represent an upper limit of VCM in
the medium. Even with exact concentration of VCM unkown, certain conclusions can be
drawn. At the lowest concentration tested (25/zM) a mutagenic response was seen equivalent
to 9mM ceo and IOmM CAA delivered extemally to the cell in the medium. This suggests
that at most, one-half of the VCM was metabolized. The lower limit cannot be determined
since intra-cellular generation of CEO and CAA may be much more efficient in terms of
mutagenic potency.
It is interesting to note that at the concentrations of CEO and CAA needed to acheive
the induced MF of 5 observed with VCM, the CAA dose should have produced detectable
toxicity (50%) while the CEO should have produced negligible toxicity (10%). In fact, no
toxicity was observed with VCM. These results suggest that the majority of induced MF
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produced by VCM must have resulted from CEO production. One must also consider that
CEO is rapidly rearranging to CAA (half-life =1.6 min at 37 * C). It is likely that a
substantial portion of the toxicity seen with CEO is due to the appearance of CAA in the
meida. An increasing body of experimental evidence from other test systems indicates that
CEO is the VCM metabolite responsible for much of its genetic activity. The data obtained
from toxicity and mutagenicity studies supports this data. It is interesting to note, however,
that in this study CEO demonstrated a mutagenic potency equal to CAA, however, CAA was
much more cytotoxic than CEO.
Impurities on the CEO included ethylene oxide and t-butyl alcohol. The contribution
of EO to the observed mutagenicity and toxicity were of concern. However, Kolman et al.,
(1992) exposed human diploid fibroblasts (VH-10) (5x10^ cells in 5ml) to EO in solution for
1 hour and then determined toxicity and hprt" mutant fraction. The lowest concentration
tested in their study was 11.02 ng/ml which produced a MF of 18x10"" The highest dose of
CEO used in the present study would have contained at most LO^g/ml EO. Therefore, EO
could account for no more that 1.5x10"" of the induced MF of 20x10" , and its contribution
to the MF is small (Kolman, et al., 1992). It is interesting to note that in comparison between
the two induced mutant fractions on a per molar basis, CEO is 25 times more mutagenic than
EO.
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Figure 4.1: See text for details
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Fig 4.2. Survival of AHH-1, P450IIE1 cells after 24 hour exposure to various concentrations
of chloroacetaldehyde. Cells were treated with CAA, returned to fresh treatment media, and a
sample was taken immediately and plated in microtiter plates at a density of 2, 4, or 30 cells
per well for 8/iM, 16mM, and 24/iM treatments respectively. Relative survival was calculated
as a fraction of the plating efficiency obtained from the treated cells relative to the plating
efficiency of the controls. Each point represents the mean of four independent experiments
each containing 3 (8mM), 6 (16mM), or 15(24/xM) independently treated cultures. Error bars
indicate the SEM of the four experiments.
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Fig 4.3. Survival of AHH-1, P450IIE1 cells after 24 hour exposure to various concentrations
of chloroethylene oxide. Cells were treated with CEO, returned to fresh treatment media, and
a sample was taken immediately and plated in microtiter plates at a density of 2. Relative
survival was calculated as a fraction of the plating efficiency obtained from the treated cells
relative to the plating efficiency of the controls. Each point represents the mean of four
independent experiments each containing three independently treated cultures. Error bars
indicate the SEM of the four experiments.
55
CO
>
3
0)
a>
>
9
3 -
2 -
1 --Y*-^-^^---------------------------- ͣ
0.5 -
0.3
n o 1                                 1
AHH-1 P4502E1
100 200 300
Delivered VCM Dose (uM)
400
Fig 4.4. Survival of AHH-1, P450IIE1 cells after 24 hour exposure to various delivered
concentrations of vinyl chloride. Cells were treated with VCM, returned to fresh treatment
media, and a sample was taken and plated in microtiter plates at a density of 2 cells per well.
Relative survival was calculated as a fraction of the plating efficiency obtained from the
treated cultures relative to the plating efficiency of the controls. Each point represents the
mean of three to five independent experiments each containing three independently treated
cultures. Error bars indicate the SEM of the experiments.
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Fig 4.5. Growth delay of AHH-1, P450IIE1 cells after 24 hour exposure to various
concentrations of chloroacetaldehyde. Cells were treated with CAA, returned to fresh media
and cell density determined. Cell counts were based on daily cell counts of individual
exposure cultures. Each treatment dose represents the mean of three independently treated
cultures. Calculated relative survival for the individual treatment doses for this experiment as
determined through plating trials was 93%, 48% and 2% for 8iiM, 16mM, and 24mM
respectively. Growth delay is represented by the non-linear portion of the graph. The
theoretical 22-hour doubling time is represented by the dotted line.
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Fig 4.6. Rates of mutation at the hprt locus in CAA treated cells. Cultures were treated in
HAT to lower the background levels of spontaneous mutants. The cells were exposed to CAA
for 24 hours and returned to fresh media. After a six day phenotypic expression period cells
were plated in microtiter plates in the presence of 6TG and scored for hprt' mutant colonies
fifteen days later. Each point represents the mean of three independent experiments each
containing 3 (8mM), 6 (16mM), or 15 (24mM) independently treated cultures. In each
experiment, induced mutant fraction was obtained by subtracting average background MF seen
in concurrent control cultures from average MF measured in treated cultures. Error bars
indicate the SEM of the three experiments. Background mutant fractions for these studies
ranged from 3.8 - 5.6x10"^.
58
(O 25
AHH-1 P4502E1
20 40 60
Delivered CEO Dose (uM)
80
Fig 4.7. Rates of mutation at the hprt locus in CEO treated cells. Cultures were treated in
HAT to lower the background levels of spontaneous mutants. The cells were exposed to CEO
for 24 hours and returned to fresh media. After a six day phenotypic expression period cells
were plated in microtiter plates in the presence of 6TG and scored for hprf mutant colonies
fifteen days later. Each point represents the mean of four independent experiments each
containing three independently treated cultures. In each experiment, induced mutant fraction
was obtained by subtracting average background MF seen in concurrent control cultures from
average MF measured in treated cultures. Error bars indicate the SEM of the four
experiments. Background mutant fractions for these studies ranged from 2.1 - 10.8x10' .
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Fig 4.8. Rates of mutation at the hprt locus in VCM treated cells. Cultures were treated in
HAT to lower the background levels of spontaneous mutants. The cells were exposed to VCM
for 24 hours and returned to fresh media. After a six day phenotypic expression period cells
were plated in microtiter plates in the presence of 6TG and scored for hprt' mutant colonies
fifteen days later. Each point represents the mean of three to five independent experimentseach containing 3 independently treated cultures. In each experiment, induced mutant fraction
was obtained by subtracting average background MF seen in concurrent control cultures from
average MF measured in treated cultures. Error bars indicate the SEM of the experiments.Dose represents the calculated cell culture concentration based on the delivered dose .
Background mutant fraction for these studies ranged from 2.1 - 5.8x10'^.
CHAPTER V
MOLECULAR ANALYSIS OF MUTANTS
INDUCED BY VCM, CEO, AND CAA
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INTRODUCTION
In order to decipher the true nature of mutation induced by the parent compound vinyl
chloride monomer (VCM) and its metabolites within the AHH-1 P450IIE1 cell line, the
mutated cells must be analyzed at the DNA level, investigating the unique pattern of changes
in the DNA. This complete evaluation of mutation at a particular genetic locus is termed the
mutational spectrum of a compound and indicates the location, frequency, and nature of
changes to the DNA resulting from exposure to chemical compounds (Benzer, 1961, Benzer,
1958, Coulondre, 1977). Mutagenic compounds show unique mutational spectra that are
different from spontaneous mutational spectrum (Schaaper et al., 1986, Liber et al., 1989.
Giroux et al., 1988). Unique spectra have been identified for many mutagenic compounds
(Skopek et al., 1982, Schaaper et al., 1986, Fuchs et al., 1981, Duane et al., 1986, Richardson
et al., 1987, Giroux et al., 1988, Drobetsky et al, 1987, Vrieliny et al., 1988, Liber et al.,
1989). The evaluation of the unique changes in the DNA can be used as a powerful tool to
provide information as to the causes of DNA point mutations in human cells (Cariello et al.,
1990).
MATERIALS AND METHODS
An overview of the process involved in analyzing DNA from VCM, CEO, and CAA
mutants is provided in figure 5.1.
Chemicals, Enzymes and Primers
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DNA preparation from mutant cells: Proteinase K, ultrapure, was obtained from
Bethesda Research Laboratories (BRL) Gaithersburg MD. Tween 20 came from lab stock.
PCR: Ample Taq DNA polymerase 5 U/m1 and 25mM MgCl2 were purchased from
Perkin Elmer Cetus. TEMED (N,N,N',N'-tetramethylethylenediamine), Acrylamide
(ultrapure), N,N' methylene bisacrylamide (BIS) (ultrapure) were obtained from Gibco BRL,
Gaithersburg Md. Tris Hydroxy-methyl Aminomethane Hydrochloride (Tris-HCL)
(Electrophoresis Grade), and Ethidium Bromide were purchased from Fisher Biotech, Fair
Lawn, N.J. Ultrapure dNTP'S from Pharmacia, LKB Biotechnology AB, International
Biotechnologies, New Haven CT. Standard used in 8% PAGE (PBR322 DNA, Mspi digest)
from New England Biolabs Beverly, Ma. Boric acid from EM Service, Gibbstown N.J.
EDTA from MaUinckrodt, Paris Kentucky. PCR primers were obtained from the Pathology
Department, University of North Carolina, Chapel Hill and were HPLC purified. The
oligonucleotide sequence and the annealing sites of the primers are given in table 5.1. Primer
concentrations were quantified on a model UV160U Shimadzu spectrophotometer (Shimadzu
Scientific Instruments, Norcross, GA) by absorbance at 260nm.
DGGE: Phenol, N,N'-metheylene bisacrylamide (BIS), and urea (enzyme grade) were
obtained from Gibco BRL, Life Tech. Inc., Gaithersberg MD. 2-mercaptoethanol, chloroform,
and formamide (molecular biology grade) were obtained from Fisher Scientific, Fair Lawn
N.J. Xylene cyanole FF; Sigma Chemical Company, StLouis MO. Bromophenol blue was
purchased from U.S. Biochemical Corp, Cleveland, OH. Analytical grade mixed resin (20-50
mesh) was purchased from Bio Rad Labs. Richmond, Va.
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DNA Sequencing All the enzymes and buffers specific for the sequencing reactions
were obtained from United States Biochemical Corp., Cleveland, OH. Ultrapure dNTP's were
from Pharmacia. The fluorescently labeled sequencing primers were prepared according to
procedures specified by Applied Biosystems.
Methods
Isolation of Mutants Treatments were completed for VCM, CEO, and CAA at doses
shown to induce mutant fractions significantly greater than background with minimal toxicity.
For isolating both VCM and CAA mutants, two consecutive treatments were accomplished at
the same treatment dose in order to achieve greater numbers of mutants. The concentrations
for VCM were 300 and 500 nM, and 16mM for CAA. The second treatment for VCM was
accomplished immediately after the first, while for CAA, the cell cultures were allowed time
to recover prior to the second treatment. Mutant frequencies for the consecutive treatments
were shown to be at least double that measured when a single treatment was completed at the
same dose. CEO mutants were isolated from a single mutation experiment of 50 mM or 75 mM.
A large enough number of mutants was achieved in a single CEO treatment. After MF plates
were scored, the cells from the colony were pipetted into eppendorf tubes, pelleted and washed
with phosphate buffered saline, and stored at -20 *' C until needed. Each colony isolated was
labeled as an individual mutant for purposes of DNA isolation and sequencing. Genomic
DNA was isolated from the cell pellet by adding "tween" cocktail, containg IxPCR buffer
(2.75 mM MgCl2,60mM KCl, 15.0 mM Tris HCl (pH 8.7) titrated to pH 8.75), 0.5% v/v
Tween 20, and 0.1 mg/ml proteinase K, in sterile distilled water. The cell pellet was
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resuspended in 20 ^1 of this mixture, incubated for one hour at 55 * C and then boiled (98' C)
for ten minutes to inactivate the proteinase K.
PCR Conditions The first PCR reactions accomplished initiated the focus on exon 3 of
hprt from genominc DNA. This was facilitated through the use of primers that annealed at the
intron sequences flanking exon 3 (Cariello et al., 1988)   To faciUtate the processing of the
large number of mutants, samples were pooled in groups of two mutants each.   Unless noted,
all PCR reactions were accomplished in 50 m1 volumes overlayed with 30 m1 mineral oil (Perkin
Elmer Cetus) and contained IxPCR buffer (as described above), 1.3x10"-^ Mg/ml of each
primer, 1.5 U AmpliTaq DNA polymerase. An additional 0.5-lmM MgCl2 was added, based
on PCR optimization studies. Final concentration of MgCl2 in the PCR reaction was between
3.25 and 3.75 mM. All PCR manipulations (less addition of DNA template) were performed
in a "clean-room" using material and equipment dedicated solely for PCR use and assumed
free of HPRT contamination. All eppendorf tubes and pipette tips were autoclaved prior to
use.  Initial PCR amplification used 2^1 total DNA template, 1 lA from each of two mutants
(this was the level of pooUng mentioned previously). All PCR reactions were accomplished in
a Perkin Elmer Cetus DNA Thermal Cycler (Model 480). The PCR thermal cycle used varied
based on the primers and concentration of template, and end amplification product. The initial
PCR cycle, for amplification of genomic DNA, consisted of one minute at 94" C, a quick ramp
to 47 * C and then one minute at 47" C, a two minute ramp to 72' C and then 30 seconds at
72" C.   Thirty-two cycles were performed. The primers used in the initial amplification from
genomic DNA were the Pj and P2 primers, as indicated in table 5-1. The results from this
PCR reaction would serve as both template for the high temperature domain PCR reaction as
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well as the product for analysis on the first low temperature domain denaturing gradient gel
(see Figure 5.1). Oil was removed from the sample and 1/10 of the sample plus 2^16x loading
buffer per sample was loaded into wells on an 8% poly aery lamide gel (37:1,
acrylamide:biscrylamide) in IxTBE buffer (lOxTBE prepared as 108g Tris Base, 55g Boric
Acid, 9.3g Na2EDTA in 11 total volume dH20). The samples were run with a size standard,
PBR322 DNA-Mspi Digest (2.0 nl of O.lMg/ml). The electophoresis conditions were 275-300
volts for approximately one hour. The gel was removed, stained for ten minutes in ethidum
bromide and destained briefly in water. A photograph was quickly taken of the gel and exon 3
bands were carefully excised using sparing long-wave UV light. The gel pieces were
individually crushed with a pipette tip and 100^1 elution mixture added (12.5 mM EDTA and
l/2xPCR buffer). The gel mixtures eluted at least 24 hours, at 4 ° C before they were used as
templates for the high temperature PCR reaction. The exon 3 PCR reaction was extracted
twice with equal volumes of phenol (equilibrated as per Maniatis et al.,1989) and then twice
with equal volumes of chloroform. The tubes were allowed to sit open in the lab hood for one
hour or were spun briefly in a Speed Vac Concentrator (Model SVC lOOH) for five minutes,
without heat to remove excess chloroform. Mutant/wild type heteroduplexes were formed by
heating the samples for ten minutes at 98' C to denature the DNA, and then incubating for
more than one hour at 37' C to reanneal. The heteroduplex formation for high temperature
melting domain PCR reactions was carried out for ten minutes at 98' C and then at 67' C
overnight to reanneal (tubes were wrapped in parafilm to preclude evaporation). After
heteroduplex formation, the samples are dried in the speed vac, with heat. The samples are
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resuspended in lixl, DGGE loading buffer (20% Sucrose, 0.3% each bromophenol blue and
xylene cyanol in autoclaved distilled H2O).
DGGE conditions The detailed methodology for preparing the denaturing gradient gel is
similar to those described in Myers et al., (1987). The glass plates are prepared, as described
using petroleum jelly on the spacers to ensure an adequate seal. The glass plates with spacers
in between are held together with large binder clips. These also facilitate leveling of the plates
which stand upright when the gel is poured. The gradient maker (SG series, Hoeffer
Scientific, San Fransisco, CA) is leveled atop a stirrer plate, with the high percentage
denaturant well centered over the stirring apparatus.   This whole apparatus is placed on a ring
stand above the level of the plates. The denaturants are prepared as follows: 150ml volumes:
18.75g polyacylamide, 0.5 g Bis, formamide is added at 10.8 ml (18%) 21.6 ml (36%), or 31.8
ml (53%) and urea is added at 11.34g (18%), 22.68 g (36%), or 33.42 g (53%), where values
in parenthesis represent percent denaturant. The volume is brought to slightly less than 150 ml
with distilled H2O, 5 grams mixed bed resin are added and the mixture stirred for 30 minutes.
Resin is filtered, 3.0 ml of 50x TAE, pH 8.3 (1.89M Tris-Base, lOOmM Tris-HCl, 0.57% v/v
glacial acetic acid) are added and the volume brought to 150 ml with H2O. This mixture is
filtered through a 0.2 uM filter and kept at 4" C until ready for use. 15.5 ml of the denaturant
mixture is pipetted into two separate Erlermyer flasks on ice. 100 nl of 10% ammonium
persulfate (APS) are added to each flask, the solution mixed gently and thoroughly degassed.
All components for pouring the gel are gathered including the appropriate size teflon comb,
N,N,N',N'-tetramethylethylenediamine (TEMED), and pipetters with tips. A small volume (2
ml) of low percent denaturant is added to the low well and the fluid is forced with thumb
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pressure into the tube. The same is done for the high percentage denaturant. The high
percentage solution is carefully poured into the high side, 3.5 m1 TEMED added and the stir
plate turned on. The same volume of TEMED is added to the low percent solution, swirled
gently and added to the low side of the gel former. Both stopcocks are opened and the gel is
allowed to drip through a very small (diameter) section of tubing between the plates to form
the gradient. Additional TEMED and APS (1.5 n\ and 10^1 respectively) are added when the
gel solution is near the top of the plates to aid in polymerization around the comb. The comb is
gently pushed in place and clamped and the gel is allowed to polymerize in the vertical
position for two hours.   For this present study one millimeter thick, 12.5% polyacrylamide
137.5:1 acrylamide: bisacrylamide 1 gels containing a linear denaturing gradient parallel to
DNA migration were used. For the low temperature domain, an 18% to 36% gradient of
denaturant was used. For resolving mutants in the high-temperature domain a 36% to 53%
gradient of denaturant was established. (100% denaturant is defined as 7 M urea plus 40% v/v
Formamide.)
After polymerizing, the gel is prepared for electrophoresis . The bottom spacer and
comb are removed, wells immediately flushed with water, and excess petroleum jelly removed
with hot water. The plates are clamped into a plexiglass frame and the frame and gel
submerged in a rectangular plexiglass tank with 141 of IxTAE which is maintained rigorously
at 60.0" C. Drastic changes in buffer pH in the upper well are prevented through circulating
the TAE buffer from the tank into the smaller well at the top of the gel with a peristaltic pump
(Myers et al., 1987).
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Immediately before loading the samples, the wells are thoroughly flushed with TAE
from the tank to remove urea that migrates out of the gel. The samples are loaded, and the
graphite cathodes placed in the top chamber. The gel is run at 150 volts with the peristaltic
pump connected to circulate the TAE overnight (approximately 15 hours). Gels were stained
with ethiduim bromide and bands visualized under sparing long-wavelength UV light. Thin
slices of the gel that contained mutant/wild-type (wt) heteroduplexes and suspected
mutant/mutant homoduplexes were carefully excised and eluted as described previously.
Heteroduplexes are usually contaminated with wild-type DNA and suspect homoduplexes
need to be verified. This is accomplished through an additional round of PCR amplification,
using 2m1 elution mixture as the template, and decreasing the number of cycles to only 20-25
because of purity and high copy number of the template (i.e. purified through the first DGGE)
versus genomic DNA. If the template from the elution of the DGGE band was a
mutant/mutant homoduplex, it will resolve on the second DGGE as only a single band in the
same location as the first. The mutant/wt heteroduplexes, cut from a single band should
resolve on the second DGGE as the full complement of bands observed fi-om the first gel
(mutant/wt heteroduplexes, wt homoduplexes, and mutant homoduplex if resolved from wt
homoduplex).  This demonstrates that the band contained mutant and wild-type DNA.
However on the second gel there will be much less wt DNA in each band. The strongest
intensity bands for each mutant are selected from the second gel, excised, crushed and eluted.
Preparation of samples for analysis in the high temperature domain are essentially similar.
The first PCR reaction uses the elution supernatant from the excised and crushed bands of the
first 8% PAGE. This PCR reaction uses the P3HI primer as the downstream, (3') primer and
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the GC5' primer for the upstream GC clamp, which makes up 40 nucleotides of the 57
nucleotide long primer. These primer sequences are given in table 5.1. The high temperature-
domain PCR reaction contains S/tig of each of these primers, 2.5 U of Taq, and 0.75 mM of
dNTP's. No additional MgCl2 is added and the template volume is 1 ul. The PCR cycle is
also slightly different: 96' C for one minute, fast ramp to 42 * C and 42 * C for one minute, two
minute ramp to 72 * C and 30 seconds at 72" C. Fifteen cycles are performed and a single
additional cycle at the same conditions but with a six minute extension time (i.e. 72" C for
6min) is included to extend all attached primers. These samples are prepared for DGGE in a
similar manner but with heteroduplex formation as previously mentioned for GC-clamped
molecules. Mutant homoduplexes from either melting domain can be taken directly to single
strand template generation for sequencing. However, for heteroduplexes the mutant strand
must first be enriched. To accomplish this eluted heteroduplex was diluted 1:50 in two
separate PCR reactions, one containing only the upstream primer (P2 for low temperature and
GC5' for high temperature analysis) and the other the appropriate down stream primer.
Fifteen PCR cycles were performed (same cycling parameters as for the appropriate high or
low first round PCR) to bias the concentration of one strand over the other. The appropriate
second primer was added and the reaction subjected to fifteen more cycles. The products of
these reactions were prepared for analysis on a denaturing gradient gel (i.e. phenol and
chloroform extractions). In order to determine which reaction had been enriched for mutant
homoduplex, an equal amount of wild-type DNA was added to each strand bias reaction prior
to heteroduplex formation. The wild-type DNA was obtained from tween prepared mutant
mixtures that clearly resolved on the denaturing gradient gel with only a wild-type band.
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After heteroduplex formation the samples were dried, and run on anther denaturing gradient
gel in tandem. When the resultant gel was irradated with UV light, the reaction that resulted in
the more pronounced (i.e. bright) heteroduplex bands was the reaction containing the most
mutant homoduplex. This difference could be seen as subtie differences in the intensity of the
bands or in the complete lack of a band suspected of containing mutant/mutant homoduplexes
depending on the efficiency of the biasing reaction.
Resolved homoduplexes, in the supernatant over the crushed denaturing gel band or in
the strand-bias PCR reaction are diluted 50-fold into a 50m1 PCR reaction containing the
appropriate downstream primer (Pj for low temperature domains and an upstream primer
(5'+C, see table 5.1) which contained a universal sequencing primer sequence attached to the
5' end of primer sequence. The GC clamp, required to analyze the sample in the high-
temperature domain is no longer needed and is removed through the use of the 5'+C primer.
The PCR reaction for the attachment of the sequencing primer used the same concentrations of
primer, buffer, dNTP's and Taq, MgCl2, and same volume template as in the initial high
temperature or low temperature exon 3 PCR respectively. Since the 5'+C primer was
designed for mouse exon 3 amplification there is a one base pair mismatch with the human
sequence annealing site; therefore annealing temperatures could not be as stringent and a 42 * C
temperature was used. For the low temperature domain reaction, the number of cycles was
optimized at twelve, with the same cycle parameters as for the first exon 3 PCR. The high
temperature domain cycle was the same as the initial P3HJ, GC5' reaction (with the extended
annealing cycle at the end of fifteen cycles). After the PCR reactions were run, the oil from
the reaction was removed and one-tenth of the reaction mixture was run on an 8%
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polyacrylamide gel to confirm the presence of product DNA. The remaining 45^1 of the
reaction was reduced by one-half in volume (in the speed-vac) combined with S/xl loading
buffer and the entire sample was run on a 1.5 mm preparative polyacrylamide gel. This gel
purified the DNA product for single strand generation by removing the large molar excess of
5'+C primer. If this was not removed, the excess primer would compete with the fluorescent
primer for binding to the ssDNA template. Bands from the preparative gel were visualized
with ethidium bromide and sparing UV light, excised from the gel and electroeluted.
Electroelution of the DNA was accomplished with an IBI unidirectional electroeluter, (model
46000), using procedures specified by the manufacturer. Briefly, up to six gel slices were
placed in the horseshoe wells of the electroeluter and almost covered with running buffer "A"
(20mM Tris HCL (pH 8.0), 0.2mM Na2EDTA, 5mM NaCl). A salt cushion of 75 m1 of
saturated NH^OAc was added to the "V"-shaped column.  Electroelution was done at 100
volts for one hour. The salt cushion containing the DNA was pipetted into 1.5 ml eppendorf
tubes. The volume was reduced to 0.1 ml and 100% cold EtOH was added to 1.5 ml. The
mixture was agitated and the samples were placed at -20 ° C ovemight (or -70 * C for 30
minutes). The samples were ethanol precipitated, 30 minute cold centrifugation, followed by a
70% EtOH rinse and 95% EtoH rinse. The sample was gendy dried in the speed vac (no heat)
and resuspended in lO/iil H2O. One-tenth of the reaction was run on an 8% polyacrylamide
gel to estimate the concentration of DNA. The amount of the remaining 9^1 resuspended
template to use in the single strand DNA reaction was determined empirically, comparing
intensity of ethiduim bromide stained gels with photographs of amounts used previously to
yield successful sequencing reactions.  The low temperature melting domain ssDNA PCR
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reactions were 50^1 in volume with the same buffer, dNTP, Taq and MgCl2 concentrations.
The final concentration of PI primer used in these reactions was 0.01 Mg/ml, which is ten
times greater than the 0.001 Mg/ml concentration used in preliminary low temperature PCR
reactions. The cycling was fast, to prevent reannealing of the template strands: 94* C for one
minute, fast to 44 * C; then 44 * C for fifteen seconds, and fast to 72 * C which was maintained
for 30 seconds. The PCR reactions were removed from the thermal cycler soon after the
reaction was complete; the oil was removed and the volume of the reaction brought to 100^1-
This was followed by two, 100^1 phenol and two, 100m1 chloroform extractions. 100^1 of 7.5
NH^OAc and 500/zl, 95% EtOH were added and the tube was inverted to mix.   The sample
was placed at -70 ° C for 20-30 minutes or -20 * C overnight. A twenty minute centrifugation at
4' C was followed by 2,200^L, 95% EtOH rinses. The sample was dried gentiy, resuspended
in 30 fd H2O, and 3m1 of the suspension was run with 2m1 loading buffer (30% glycerol, 0.6%
SDS, 0.6% xylene cyanol, 0.06% BBPh, and 60mM EDTA) on an 8% polyacrylamide gel.
Single-strand DNA bands were visualized above the double stranded bands.   Sequencing
reactions were accompUshed using an empirically determined volume of single strand
suspension (determined through estimation of ethidium bromideAJV band intensity).
Sequencing procedures were identical to those suggested by Applied Biosystems for use with
their automated sequencer.
RESULTS
118 VCM induced hprt" mutants from two independent experiments were analyzed by
DGGE in both the low and high temperature domains. 3.3% (4 isolates) in the high
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temperature domain displayed by the same banding pattern. This pattern was not identified in
any of spontaneous mutants analyzed. 8.5% (10 isolates) in the low temperature domain had
the same banding pattern, while only 1.2% (1 isolate) of the VCM spontaneous had the same
pattern. 196 CEO mutants were analyzed in the low temperature domain and 5.6% (11
isolates) of the CEO mutants resolved with a banding pattern identical to VCM. None of the
CEO spontaneous mutants (15 mutants total) and only one of the CAA spontaneous mutants
(43 spontaneous mutants total) had this banding pattern.
The VCM "hotspots" in the low- and high-temperature melting domain were sequenced.
Four different mutants that gave identical DGGE banding patterns in the low temperature
domain were sequenced. The sequence change identified in all of these mutants was a G-»T
transversion at base pair 292 (see Fig 5.2). Three different mutants that gave identical DGGE
high temperature domain banding patterns were also sequenced. The sequence change
identified in all three of these mutants was a G->A transition at base pair 197.
DISCUSSION
We have used the polymerase chain reaction (PCR), denaturing gradient gel electrophoresis
(DGGE), and automated dideoxy termination DNA sequencing to analyze hprt" exon 3
mutants from VCM, CEO, and CAA treated AHH-1 cells expressing cytochrome P450IIE1
activity. Analysis of all mutants expressed within exon 3 was made possible through the PCR
attachment of G+C rich sequence (GC-Clamp) during amplification of exon DNA. This clamp
allowed for complete analysis in both the high and low temperature melting domains of exon
3.
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DGGE analysis of VCM-induced 6TG'^ cells revealed potential mutational "hotspots" in
both the high and low temperature domain in hprt exon 3. The "hotspot" in the low
temperature domain was identified in 8.5% of the VCM mutants analyzed, and 5.6% of the
CEO mutants, hi analysis of the high temperature domain, the potential "hotspot" was
identified in 3.3% of the VCM, mutants.   The analysis of the spontaneous mutants from the
three different experiments in the low temperature melting domain indicates that these two
mutational "hotspots" are enriched in treated cultures. The fact that the M.F. in treated culture
were 2 to 3.5 fold higher than in concurrent controls controls makes the difference in hotspot
percentages even more significant. The mutational events at bp 292 and 197 affected a single
amino acid, aspartate and cysteine respectively.   The G->T transversion at bp 292 and the
G-»A transition at bp 197 would result in the insertion of the amino acid tyrosine at each of
these locations.
The two groups of VCM induced mutants that were analyzed were from different
treatment concentrations from the same experiment. Each of these treatments had similar
induced MF and the average background MF was 5.5x10'". The experiment had two
consecutive (equal) delivered doses of 300 mM or 500 mM from which mutant cells were
collected for analysis.
The G-»A transition at base pair 197 in the high temperature domain is consistent with
the observed miscoding of N'',3eG seen in vitro, and is most likely the responsible adduct.
The G-»T transversion at base pair 292 in the low temperature melting domain is not consistent
with the miscoding potential of N"',3 eG. It may be due rather to the formation of an apurinic
site from 7-OEG and the misinsertion of adenine in the daughter strand (Swenberg et al..
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1990). The responsible adduct could also be eCyd, causing a C->A transversion (as
demonstrated in vitro in the opposite strand, appearing like a G-»T transversion. However, the
possibility does exist that N ,3 eG has miscoding potential in human cells other than the G:T
pairing seen in vitro which gives rise to a GC-AT transition (Singer et al., 1987).
Mutation Analysis Summary
1
hlSOLATE   1MlVIUTANTSl
Low Temperature Domain
lU
O
§
'^ Exon 3 PCR
Phenol/CHCiS Extract
Heteroduplex
DGGE
Crushate
High Temperature Domain
___^    8% PAGE - Cut Bands
GC-ClampPCR  "
Phenol/CHCI3 Extract
Mutant/IUIutant
HOMODUPLEXES
Strand Bias PCR
i
Phenol/CHCIS Extract
Heterduplex Formation
DGGE
Select 5' or 3' Strand
5' PCR Reaction
Heteroduplex
—  DGGE
UJ
O
o
Q
Crushate
Strand
Reactions
1.5mm Preparative Gel
Cut Bands Electroelute EtOH Precipitate
Single-Strand DNA PCR Reactions
Sequence Reactions with C primers
Automated Dideoxy DNA Sequencing
Figure 5.1 See text for details
77
Sequences of Primers Used for PCR and Sequencing
Designation of human hprt annealing sites are as published (Edwards, 1990)
Primer Length
PCR Primers:
PI 20mer
P2 20mer
P3Hi 17mer
GCS'mus 57mer
Sequence (5' to 3') Annealing Site
Sequencing Primer:
C 22mer
CATATATTAAATATACTCAC 16806-16787
TCCTGATTTTATTTCTGTAG 16583-16602
TCCAGCAGGTCAGCAAA 16691-16707
CCGCGGGCGGGCCTCGCGC 16583-16602
CGCGGGCCGGGACCCGCGG
CCTGATTTTATTTCTATAG
CAGGAAGACAT
TCTTTCCAGTT
Table 5.1
Model 373A
\f&s\on^.02
Copy of Sample 09
DyePrimer|M13RP1|
Lane 9
Signal: C:418 A:469 G258 T:106
Points 728 to 3604   Base 1:728
370a#904405
L-L 47/48
VCM LO TEMP HOMODUPLEX
Tue, Apr 14,1992 650 PM       Page 1 of 1
X:0to3047 Y:0to1200
ATTTTATTTCTATAGGACTGAACGTC TTGCTCGAGATGTGATGAAGGAGATGGGAGQCCATCACATTGTAGCCCTC TGTGTGC TCAAGGGGGGCTA TAAATTC T TTO
TGACCTGCTGGATTACATCAAAGCACTGAATAGAAATAGTGATAGATCCATTCCTATGACT6TATATTTTATCAGACTGAAGAGCTATTGTGTGNNNCTATTTAAT
G to T
ol ͣ^LwU
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CHAPTER VI
CONCLUSIONS
AND
SUMMARY
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We analyzed toxicity, mutagenicity and the mutational spectra in AHH-1 cells with IIEl
metabolizing capabilities following treatment with VCM, CEO and CAA. A dose related
toxicity was evident from both CAA and CEO treatments, however, no toxicity was evident
with VCM treatments at levels limited by solubility. In this study the relative toxicities of the
three compounds were CAA>CEO»VCM.
A dose related increase in MF was observed for CAA and CEO. In the human cells
used in this experiment the mutagenic potency of CAA was found to be almost equal to CEO,
an observation not demonstrated in other systems. Mutant fraction response did not
monotonically increase for VCM, however, increased concentrations of VCM typically led to
an increased MF measured with no toxicity measured at any dose. MF in the VCM
experiments reached a plateau at approximately 5 x 10" . Comparison of mutation
frequncy/survival ratios for CEO and CAA at a MF of 5 suggest the majority of mutations
induced by VCM must be produced by CEO.
Analysis of these mutants led to the identification of a suspected VCM mutational "hot
spot" in both the low and high temperature domains of hprt exon 3. The DNA sequence
changes identified in the VCM mutants that exhibited "hot spots" revealed a G-»T transversion
in bp 292 in the low temperature melting domain and a G-»A transversion at bp 197 in the high
temperature melting domain. In vitro studies suggest the transversion in the high temperature
domain was caused by the N'^,3 eG adduct. The transversion identified in the low temperature
domain may be the result of an apurinic site from 7-OEG, a C-+A transversion in the opposite
strand from eCyd, or a yet unidentified change caused by N^,3 eG.
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Two pieces of experimental data obtained from this study support the hypothesis that
CEO is the more important mutagenic metabolite of VCM. 1) The comparison of induced MF
from VCM, CEO and CAA indicated that only CEO could produce the ratio of mutagenicity
and toxicity seen with VCM. 2) One of the mutational "hot spots" identified in VCM was
seen at a significant rate in CEO mutants.
During the course of this study, the VCM treatment regime was constantly modified.
This reflects the complexities involved in the VCM treatment, not the least of which was
optimizing MeOH concentrations. All references to VCM treatments (and the others as well)
referred to a delivered dose of the compound. The reliability in delivering a calculated
concentration of CAA was high, since CAA is water soluble and treating the cell cultures was
relatively straight forward. These conclusions cannot be said about the VCM treatments. As
the experimentation progressed with VCM, we found it crucial to keep the VCM stock and
dosing solutions very cold. During several early treatments when this was not done, the dose
of VCM measured in the syringe was completely expelled by VCM gas coming out of
solution. This was a problem that was effectively countered only in the last two treatments.
Keeping the VCM solutions cold should also allow different MeOH concentrations to be
optimized for the stock solution in future work involving VCM treatments with this cell line,
precluding any possibility of MeOH inhibition of IIEl activity. We analyzed MeOH
concentrations at the highest delivered VCM dose and found a tendency for MF to be
inversely related to MeOH concentrations in the cell suspension. Comparing the effect of
MeOH concentrations on another test substance with known MF may not be appropriate
because of the potential for different metabolic efficiencies between the test substances. The
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reported level of MeOH inhibition of P450nEl was 0.03% (Gentest, 1990). Treatments with
CEO were also complex as the pure CEO needed to be diluted in dosing solutions at the
appropriate concentrations and administered quickly before it could rearrange to CAA.
One future course of study from this project would be the sequencing of all the VCM,
CEO, and CAA mutants that exhibited different DGGE banding patterns to obtain the
complete mutational spectra for these three compounds and to validate the mutational
"hotspots".   Additionally, the direct quantification and comparison of adducts resulting from
VCM, CEO, and CAA would be important to characterize the adducts responsible for the
observed mutations. Cells from each of the three analyzed treatments were collected, pelleted
and frozen directly after treatment for such a purpose.
The analysis of mutation frequency, toxicity and mutational spectra in the AHH-1 cell
line with P450IIE1 metabolic activity exposed to VCM, CEO, and CAA gives additional
evidence as to the relevant metabolite potentially responsible for the known carcinogenic
actity of VCM. This information may be useful in the future development of biomarkers of
human VCM exposure.
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